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ABSTRACT 
Background. Human chorionic go-
nadotropin (hCG) is a placental gly-
coprotein hormone consisting of α 
and β subunits. HCG is in clinical use 
in the management of pregnancy and 
in trophoblastic diseases. The free β 
subunit (hCGβ) has been shown to 
be expressed in various non-
trophoblastic cancers, including di-
gestive tract malignancies, and pre-
vious studies have suggested that 
hCGβ may be a useful tumour 
marker for these malignancies. 
Aims. In the present study, the tis-
sue expression of hCGβ was investi-
gated by immunohistochemistry in 
various gastrointestinal cancers and 
benign tissues. In addition, hCGβ in 
serum was evaluated in gastrointes-
tinal diseases and its diagnostic 
value was compared with carcinoem-
bryonic antigen (CEA) and CA 19-9. 
Furthermore, the prognostic value of 
serum hCGβ was assessed and com-
pared with the prognostic value of 
tumour markers CEA, CA 19-9, CA 
242, and CA 72-4 in colorectal, gas-
tric and pancreatic cancer, three of 
the most common digestive tract 
cancer forms in developed countries. 
Patients. Tissue samples were ob-
tained from 107 patients with various 
gastrointestinal malignancies and 
from 36 patients with benign or nor-
mal tissue samples. For the diagnos-
tic evaluation, serum samples were 
obtained from 142 patients with 
various malignant and 178 with be-
nign gastrointestinal diseases. For 
the prognostic evaluation, preopera-
tive serum samples were obtained 
from 204 patients with colorectal, 
146 patients with gastric, and 160 
patients with pancreatic cancer.  
Methods. A monoclonal antibody 
(MAb) specific for free hCGβ was ap-
plied in the immunohistochemical 
study to detect the tissue hCGβ. The 
specificity of the staining was verified 
and the results were compared with 
those obtained with a widely used 
commercial polyclonal antibody 
(PAb) reacting with both free hCGβ 
and intact hCG, as well as with β-
subunit of luteinizing hormone (LHβ). 
Serum hCGβ was measured with an 
in-house immunofluorometric assay 
(IFMA) based on the same MAb spe-
cific for the free hCGβ subunit, with 2 
pmol/L as a cut-off value. The quan-
tification of CEA, CA 19-9, CA 242, 
and CA 72-4 in serum was performed 
with commercial kits with cut-off val-
ues of 5 µg/L for CEA, 35 or 37 kU/L 
for CA 19-9, 20 kU/L for CA 242, and 
6 kU/L for CA 72-4. The diagnostic 
values of the markers were com-
pared with logistic regression (LR) 
analysis. Survival analysis was per-
formed with univariate Kaplan-Meier 
life-tables and log-rank test, and 
with multivariate Cox regression 
analysis. 
Results. Immunohistochemical ex-
pression of hCGβ was observed most 
frequently in gastric (60%) and pan-
creatic (56%) carcinomas, and in 
extrahepatic cholangiocarcinomas 
(36%). In addition, staining was ob-
served in samples from benign pan-
creatic and biliary tissues.  
In serum, hCGβ level was elevated 
most frequently in bile duct (56%), 
pancreatic (45%), and gastric cancer 
(41%). In benign diseases, the hCGβ 
concentration in serum was elevated 
in 10% of the patients. In a LR 
model, each of the markers CEA, CA 
19-9 and hCGβ provided independent 
diagnostic information, and the cal-
culated probability of cancer index 
provided better accuracy than the 
markers alone. In receiver operating 
characteristic (ROC) curve analysis, 
the area under the curve (AUC) value 
of the index was significantly higher 
than the AUC values of hCGβ, CEA, 
or CA 19-9 (p< 0.049). In univariate 
survival analysis, hCGβ was observed 
to be a prognostic factor in colorec-
Johanna Louhimo 
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tal, gastric and pancreatic cancer 
(p< 0.001). In Cox multivariate 
analysis, hCGβ was found to be the 
strongest prognostic marker of the 
studied markers in colorectal, gastric 
and pancreatic cancer. 
Conclusions. HCGβ is expressed in 
malignant digestive tract tissues in-
cluding pancreatic adenocarcinoma, 
as well as in benign pancreatic and 
biliary tissues. In gastrointestinal 
malignancies, serum hCGβ provides 
additive diagnostic information to CA 
19-9 and CEA, and the use of an al-
gorithm established by logistic re-
gression analysis improves the diag-
nostic accuracy compared to the in-
dividual markers. Serum hCGβ is an 
independent prognostic factor in co-
lorectal, gastric and pancreatic can-
cer. These results substantiate previ-
ous findings that hCGβ is a potential 
serum tumour marker for digestive 
tract malignancies. 
  9
INTRODUCTION 
Digestive tract malignancies are im-
portant causes of cancer-related 
morbidity and mortality. In devel-
oped countries, the most common 
digestive tract cancers are colorectal, 
gastric, and pancreatic cancer. In all 
gastrointestinal cancers, the role of 
surgery is essential and radical surgi-
cal resection has been the potentially 
curative treatment with positive im-
pact on survival. Therefore, the 
anatomic extent of the disease, rep-
resented by stage of the tumour, and 
the possibility of performing surgical 
resection with intent to cure have 
been the established prognostic fac-
tors. However, with the development 
of more effective chemo- and radio-
therapies, additional prognostic and 
predictive factors, such as tumour 
markers, could emerge as useful 
tools for the clinician in selecting pa-
tients for different adjuvant treat-
ment regimens. Apart from the 
evaluation of prognosis of the dis-
ease, tumour markers may be useful 
in primary diagnosis of cancer and of 
recurrence of the disease, and in the 
monitoring of the response to treat-
ment.  
Human chorionic gonadotropin (hCG) 
is a glycoprotein hormone produced 
at high concentrations by the pla-
centa during pregnancy. It is also a 
very sensitive marker for trophoblas-
tic tumours. HCG consists of an α 
and a β subunit, and the free β sub-
unit (hCGβ) has been shown to be 
expressed in many non-trophoblastic 
tumours, including gastrointestinal 
cancers. In addition, it has been 
suggested that hCGβ may be a prog-
nostic factor in various digestive 
tract malignancies. 
 
The present study was carried out to 
verify previous findings and to inves-
tigate the tissue and serum expres-
sion of hCGβ in gastrointestinal ma-
lignancies with a sensitive and spe-
cific monoclonal antibody. Further-
more, the aim was to ascertain the 
prognostic value of serum hCGβ in 
colorectal, gastric and pancreatic 
cancer, which are recognized as 
three of the most common digestive 
tract cancers in developed countries. 
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REVIEW OF THE LITERATURE 
Chemistry and biology of 
chorionic gonadotropin and 
its subunits 
Human chorionic gonadotropin is a 
member of a glycoprotein hormone 
family that includes the three ante-
rior pituitary hormones luteinizing 
hormone (LH), follicle stimulating 
hormone (FSH) and thyroid stimulat-
ing hormone (TSH). These glycopro-
tein hormones are heterodimers con-
sisting of two distinct non-covalently 
bound subunits, α and β. The α-
subunits are identical in these glyco-
protein hormones, whereas the β-
subunits are specific, though ho-
mologous, for individual hormones 
accounting for the biological charac-
teristics and specific activities of the 
hormones. The 3-dimensional struc-
ture of hCG contains a cystine-knot 
motif that resembles certain protein 
growth factors, namely nerve growth 
factor (NGF), transforming growth 
factor β (TGF-β) and platelet-derived 
growth factor β (PDGF-β) (Lapthorn 
et al., 1994). 
 
The hCGα-subunit comprises 92 
amino acids and contains two N-
linked oligosaccharide side chains 
attached at amino acid residues 52 
and 78. The β-subunit has 145 amino 
acids and contains two N-linked car-
bohydrate side chains at residues 13 
and 30, and four O-linked side chains 
at residues 121, 127, 132, and 138 
(Morgan et al., 1975). The figure 1 
illustrates schematically the linear 
structure of hCGα and hCGβ and its 
degradation products nicked hCGβ 
(hCGβn) and β-core fragment hCGβ 
(hCGβcf) (Alfthan & Stenman, 1996; 
Cole, 1997; Berger et al., 2002). 
 
Figure 1. Schematic representation of hCGα 
and hCGβ and its variants. Numbers indicate 
the number of an amino acid residue in the 
polypeptide chain, and S-S illustrates disulfide 
bonds. hCGβn= nicked hCGβ; hCGβcf= β-core 
fragment of hCGβ; CTP= carboxy-terminal 
peptide; CHO= carbohydrate side chain. 
Adopted and modified from Berger et al. 
(2002) and reproduced with the permission of 
the publisher S. Karger AG, Basel. 
 
Of the glycoprotein hormones, hCG is 
the most heavily glycosylated, with 
approximately 30% carbohydrate 
content by weight. The total molecu-
lar weight of the hCG molecule is 
36.7 kDa, of hCGα 14.5 kDa, and of 
hCGβ-subunit 22.2 kDa (Birken, 
1984). In addition, the molecular 
epitope structure of hCG and its α- 
and β-subunits has been character-
ized in detail, along with several 
monoclonal antibodies (MAbs) di-
rected against hCG and its subunits 
and their variants (Berger et al., 
2002). Some of the epitopes on the 
hCGβ disappear upon the composi-
tion of intact hCG. Consequently, 
depending on the epitope they iden-
tify, the hCGβ MAbs detect either the 
β-subunit only, or both hCGβ and 
hCG (Berger et al., 2002).  
 
The α-subunit is encoded by a single 
gene, which is located in chromo-
some 6q21.1-23 (Fiddes & Goodman, 
1979; Boothby et al., 1981; Jameson 
CTP
S - S
1 145113
S - S
1 145113
core fragment
S - S
6 9255
S - S
1 92
44 48
40
CTP
hCG?
hCG?n
hCG?cf
hCG?
O-linked CHO
N-linked CHO
truncated CHO
Z
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& Hollenberg, 1993). The β-subunit is 
encoded by a cluster of six non-allelic 
genes or pseudogenes located in 
chromosome 19q13.3, which is in the 
same locus as the β-subunit of LH 
(LHβ) gene (Boorstein et al., 1982; 
Policastro et al., 1983; Talmadge et 
al., 1983; Jameson & Hollenberg, 
1993). At least five of the genes en-
coding the β subunit are transcribed 
in vivo (Bo & Boime, 1992). With the 
reverse transcriptase -polymerase 
chain reaction (RT-PCR) technique it 
has been shown that hCGβ-genes are 
expressed in various non-
trophoblastic tissues, both in neo-
plastic and normal tissues (Bellet et 
al., 1997; Yokotani et al., 1997). In 
cancerous tissues, only certain hCGβ 
genes are activated whereas other 
genes are expressed mainly in nor-
mal tissues (Lazar et al., 1995; Bel-
let et al., 1997). The activation of 
certain genes is suggested to have 
prognostic significance in breast can-
cer (Bièche et al., 1998). 
 
Biological function of hCG and 
its subunits 
HCG is normally secreted by syncyti-
otrophoblast cells of the placenta and 
it is an essential hormone in main-
taining pregnancy. During the first 
trimester, it stimulates the proges-
terone production of the corpus lu-
teum (Yoshimi et al., 1969) and the 
testosterone production of the foetal 
testes (Huhtaniemi et al., 1977). In 
vitro, hCG has been shown to induce 
proliferation of normal uterine leio-
myomal and myometrial smooth 
muscle cells (Horiuchi et al., 2000). 
A recent study has also suggested 
that hCG induces neovascularization 
and acts as an angiogenic factor in 
uterine adaptation to early preg-
nancy and in tumour development 
(Zygmunt et al., 2002). 
 
Appropriate glycosylation is a pre-
requisite for the full expression of the 
biological activity of hCG in vivo. The 
hormonally active form of hCG is the 
intact heterodimer of α (hCGα) and β 
(hCGβ) subunits, whereas the free 
subunits lack gonadotrophic effects 
(Rayford et al., 1972; Catt et al., 
1973). HCGβ and LHβ are highly ho-
mologous; furthermore, hCG and LH 
elicit their hormonal actions interact-
ing with a common LH/hCG receptor. 
The receptor is a G-protein coupled 
transmembrane receptor with a large 
extracellular domain, which consti-
tutes the binding site of hCG and LH 
hormones (McFarland et al., 1989). 
Subsequent to receptor binding, the 
hormones bring forth their the bio-
logical effects by a ligand-induced 
change in the conformation of the 
receptor followed by activation of 
intracellular adenylate cyclase. This 
results in an increase in adenosine 
3’,5’-monophosphate (cAMP) content 
which finally leads to an increase in 
steroid synthesis and production 
(Segaloff & Ascoli, 1993; Puett et al., 
1996). 
 
The true biological function of the 
free subunits of hCG in neoplastic 
disease is unknown. Nevertheless, it 
has been shown that in vitro hCGβ 
stimulates the phospholipid methyla-
tion in Leydig cells (Ronco et al., 
1993), stimulates the growth of tu-
mour cells (Gillott et al., 1996), and 
inhibits apoptosis (Butler et al., 
2000). Furthermore, expression of 
hCGβ has been proposed as a pheno-
typic characteristic of neoplastic cells 
(Acevedo et al., 1995; Regelson, 
1995). Endogenous hCGβ has been 
suggested to have an auto- or 
paracrine effect on tumour cell 
growth (Gillott et al., 1996), but the 
mechanism for this possible action is 
unclear because hitherto no recep-
tors have been identified for the free 
hCGβ. In addition, ββ-homodimers 
have been shown to exist in vitro, 
but the possible biological activity 
and functions of this homodimer re-
mains to be determined (Butler et 
al., 1999).  
Johanna Louhimo 
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Clinical use of hCG determi-
nations 
Normal pregnancy 
The measurement of hCG is in wide-
spread use in the diagnosis and fol-
low-up of pregnancy and pregnancy 
related disorders. Pregnancy can be 
diagnosed by detecting an elevated 
concentration of hCG in the serum or 
urine after the first missed menstrual 
period. Following conception, the 
concentration of hCG in serum starts 
to increase 7 to 11 days after ovula-
tion. During the first six weeks after 
the last menstrual period, the in-
crease is nearly exponential with a 
doubling time of 1.5 days. The peak 
in hCG concentration is evident at 7-
10 weeks of pregnancy. Thereafter 
the concentrations decrease until the 
beginning of the second trimester, 
wherein a moderate and gradual in-
crease occurs towards term (Marshall 
et al., 1968; Braunstein et al., 1976; 
Lenton et al., 1982; Pittaway et al., 
1985). The concentrations of hCGβ in 
serum during pregnancy have a simi-
lar profile to concentrations of intact 
hCG (Alfthan et al., 1988). However, 
following delivery the concentration 
of intact hCG returns to baseline in 
about 21 days, while the elimination 
of hCGβ is markedly slower (Korho-
nen et al., 1997).  
 
Pregnancy related disorders 
The incidence of an early spontane-
ous abortion is 20-25% of all concep-
tions (Wilcox et al., 1988). In rela-
tion to early foetal loss, the hCG 
concentration may initially increase 
normally before its obvious decline 
after abortion (Braunstein et al., 
1978). However, it is noteworthy 
that following a spontaneous abor-
tion, the return of hCG levels into the 
reference range may take up to 35 
days (Steier et al., 1984). Nonethe-
less, hCG continues to be the most 
relevant marker of pregnancy and 
therefore also of spontaneous preg-
nancy loss (O'Connor et al., 1994). 
 
Ectopic pregnancy is usually diag-
nosed by ultrasonography (US) with 
no visible intrauterine gestational sac 
in patients with elevated hCG values 
(Cacciatore et al., 1990). In patients 
with ectopic pregnancy the serum 
hCG concentration may be lower 
than during a normal pregnancy, but 
it may also be normal for a long time 
(Rayford et al., 1972; Braunstein et 
al., 1978). 
 
In foetal trisomy 21 (Down’s syn-
drome), maternal serum concentra-
tion of hCG is commonly elevated, 
whereas the concentrations of α-
foetoprotein (AFP) and oestriol are 
simultaneously decreased. The com-
bined measurement of these markers 
has been applied in the screening of 
trisomy 21 (Wald et al., 1988). How-
ever, sensitivity of the free hCGβ has 
been shown to be superior to intact 
hCG in detecting Down’s syndrome 
pregnancies (Spencer, 1991). Fur-
thermore, the combination of mater-
nal age, and AFP and hCGβ serum 
measurements (Crossley et al., 
1991; Spencer et al., 1992; Nør-
gaard-Pedersen et al., 1994), as well 
as the combined measurement of 
hCGβ and inhibin A have improved 
the diagnostic accuracy (Wald et al., 
1996). 
 
Gestational trophoblastic disease 
and germ cell tumours 
Neoplastic cells of trophoblastic ori-
gin produce hCG, which makes it a 
useful tumour marker for choriocar-
cinoma and other embryonal tu-
mours such as teratomas (Bag-
shawe, 1992; O'Connor et al., 1994; 
Alfthan & Stenman, 1996). Com-
pared to normal pregnancies, the 
molecular diversity of hCG is more 
extensive in trophoblastic pregnan-
cies (Cole et al., 1994). The propor-
tion of free hCGβ and intact hCG can 
be applied in differentiating benign 
Review of the Literature 
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molar disease (ratio less than 5%) 
from choriocarcinoma (ratio more 
than 6%). The ratio of hCGβ to hCG 
in trophoblastic diseases, from the 
highest to lowest, are choriocarci-
noma, benign complete hydatidiform 
mole, partial hydatidiform mole, and 
normal pregnancy (Fan et al., 1987; 
Ozturk et al., 1988; Rinker & Tietz, 
1989). 
 
Approximately 20% of ovarian and 
90% of testicular tumours are of 
germ cell origin (Talerman, 1985). In 
ovarian germ cell tumours, AFP and 
hCG are applied routinely in the di-
agnosis and management of the dis-
ease (Zalel et al., 1996). Testicular 
germ cell tumours are further classi-
fied into seminomas and non-
seminomatous germ cell tumours 
and both types produce hCG and/ or 
hCGβ, which are recommended for 
monitoring the disease (Braunstein 
et al., 1973; Saller et al., 1990; Mar-
cillac et al., 1992; Madersbacher et 
al., 1994). Recently hCGβ was sug-
gested to be superior to hCG in sen-
sitivity in seminomas, whereas hCG 
was more sensitive than hCGβ in 
non-seminomatous testicular tu-
mours (Hoshi et al., 2000). 
 
Expression of free β-subunit of 
human chorionic gonadotro-
pin 
HCGβ in healthy subjects and in 
benign conditions 
The serum levels of hCGβ in healthy 
subjects are normally low (< 2 
pmol/L) (Alfthan et al., 1992a). 
HCGβ is expressed at low levels in 
the pituitary (Hoermann et al., 1990) 
and positive immunostaining of hCGβ 
has also been reported in normal and 
inflammatory gastric tissues (Manabe 
et al., 1985; Yakeishi et al., 1990), 
and in normal pancreatic ductal epi-
thelium (Graeme-Cook et al., 1990). 
In addition, normal tissues of breast, 
prostate, skeletal muscle, bladder, 
adrenal glands, thyroid, colon, and 
uterus, have been shown to express 
hCGβ genes (Bellet et al., 1997). The 
same report also suggested that 
some immunoassays for hCGβ fail to 
be sensitive enough to detect the 
secretion of hCGβ by normal cells, 
which have low transcriptional activ-
ity of hCGβ genes.  
 
Table 1. Upper reference limits (pmol/L) for 
hCG and hCGβ in serum and in urine in 
healthy subjects (Alfthan et al., 1992a). 
Age (years) < 50 ≥50 <50 ≥50 
Serum Women Men 
hCG 8.6 15.5 2.1 6.1 
hCGβ 1.6 2.0 1.9 2.1 
Urine     
hCG 8.8 11.5 2.9 8.4 
hCGβ 1.7 4.3 1.3 3.6 
 
Moderately elevated serum levels of 
intact hCG have been demonstrated 
in patients with enteritis, ulcerative 
colitis, gastric and duodenal ulcers, 
and in liver cirrhosis (Vaitukaitis et 
al., 1976; Hoermann et al., 1992). 
The concentration of free hCGβ sub-
unit in serum has been reported to 
be elevated in some benign condi-
tions, such as pancreatitis and be-
nign biliary obstruction (Alfthan et 
al., 1992b; Syrigos et al., 1998). 
 
HCGβ in malignant diseases 
Various non-trophoblastic malignan-
cies have been shown to express 
hCG or its free β subunit (Braunstein 
et al., 1973; McManus et al., 1976; 
Hattori et al., 1978; Blackman et al., 
1980; Marcillac et al., 1992). HCGβ 
has been proposed to be a useful 
tumour marker in gastrointestinal, 
bladder, renal, ovarian, and lung 
cancers, with high serum levels as-
sociating with adverse prognosis 
(Iles & Chard, 1991; Marcillac et al., 
1992; Webb et al., 1995; Carpelan-
Holmström et al., 1996a; Webb et 
al., 1996; Syrigos et al., 1998; 
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Lundin et al., 2001; Vartiainen et al., 
2001; Hotakainen et al., 2002). Tu-
mours producing hCGβ have also 
been suggested to be more aggres-
sive in nature and more resistant to 
therapy than hCGβ negative tumours 
(Campo et al., 1987; Moutzouris et 
al., 1993). In addition, the role of 
hCG has been evaluated in differen-
tiating malignant from benign effu-
sions in patients with hematological, 
gastrointestinal, gynecological, pul-
monary, urological, and other miscel-
laneous malignant and benign dis-
eases. With an assay detecting both 
free hCGβ and intact HCG, measure-
ment of hCGβ was shown to be use-
ful in ascitic and pleural effusions 
improving diagnostic accuracy par-
ticularly in cytology-negative effu-
sions (Lamerz et al., 1999). In an-
other report on several non-
trophoblastic malignant tumours, an 
assay for the free hCGβ was shown 
to be useful in distinguishing malig-
nant from benign ascites (Hoermann 
et al., 1992). 
 
HCGβ in digestive tract malignan-
cies 
A positive hCGβ immunoreactivity in 
tissues has been observed in several 
digestive tract malignancies, includ-
ing in 21 to 33% of oesophageal 
squamous cell carcinomas (Burg-
Kurland et al., 1986; Trias et al., 
1991), in 14 to 53% of gastric carci-
nomas (Manabe et al., 1985; Wit-
tekind et al., 1986; Fukayama et al., 
1987b; Yakeishi et al., 1990; Webb 
et al., 1996), in 17 to 52% of colo-
rectal carcinomas (Shousha et al., 
1986; Campo et al., 1987; Fuka-
yama et al., 1987a; Yamaguchi et 
al., 1989; Connelly et al., 1993; 
Webb et al., 1995; Kido et al., 
1996), in 15 to 23% of cholangiocar-
cinomas (Nakanuma et al., 1986; 
Nonomura et al., 1989), and in 2% 
of hepatocellular carcinoma (Na-
kanuma et al., 1986). However, to 
the best of the author's knowledge, 
the incidence of tissue expression of 
hCGβ has not previously been re-
ported in pancreatic cancer.  
 
Elevated levels of hCGβ in serum in 
digestive tract malignancies have 
been demonstrated in 21% to 52% 
of patients with gastric (Birkenfeld et 
al., 1989; Webb et al., 1996), 16% 
to 36% with colorectal (Mercer & Ta-
lamo, 1985; Birkenfeld et al., 1989; 
Webb et al., 1995), and in 42% with 
pancreatic cancer (Syrigos et al., 
1998). In most studies, however, the 
applied hCGβ antibodies have been 
polyclonal which are known to cross-
react with intact hCG. Studies on an-
tibodies specific for free hCGβ have 
shown elevated levels in 9% of gas-
tric (Marcillac et al., 1992), 17% of 
colorectal (Carpelan-Holmström et 
al., 1996a), 11% of hepatocellular 
(Marcillac et al., 1992), 86% of bil-
iary (Alfthan et al., 1992b), and in 
30% to 72% of pancreatic cancer 
patients (Alfthan et al., 1992b; Mar-
cillac et al., 1992). 
 
Molecular detection of hCGβ in 
neoplasms 
With the improvement in molecular 
cloning techniques, more sensitive 
molecular detection of hCGβ has be-
come possible. Expression of hCGβ 
messenger RNA (mRNA) has been 
demonstrated with RT-PCR on circu-
latory metastatic cells in patients 
with breast and pancreatic cancer 
(Hoon et al., 1996; Bilchik et al., 
2000; Hu & Chow, 2000; Taback et 
al., 2001), and with trophoblastic 
and germ cell tumours (Hautkappe et 
al., 2000; Taniguchi et al., 2000; 
Hara et al., 2002; Suzuka et al., 
2002). In colorectal cancer sentinel 
nodes have been evaluated with mo-
lecular profiling, and expression of 
hCGβ mRNA was evident in the 
nodes along with other molecular 
markers (Bilchik et al., 2001; Bilchik 
et al., 2002). In future, these tech-
niques may be clinically applicable in 
assessing the prognosis and identify-
ing patients with high risk of recur-
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rence, as well as in the earlier detec-
tion of disease progression and 
monitoring response to treatment. 
 
Colorectal cancer 
Epidemiology of colorectal cancer 
Worldwide, colorectal cancer is the 
most common gastrointestinal cancer 
and it is an important cause of can-
cer related death having accounted 
for more than 490,000 deaths in 
year 2000 (International Agency for 
Research on Cancer, 2001). In de-
veloped countries its age-adjusted 
incidence was 37.3/ 100 000 in 
males and 25.4/ 100 000 in females 
(International Agency for Research 
on Cancer, 2001). In Finland in the 
last few decades, only moderate 
changes have occurred in the inci-
dences of colon or rectal cancer (Fin-
nish Cancer Registry, 2003). How-
ever, over a longer time span of 
about 50 years, the incidences have 
been gradually increasing. In the 
year 2000 colon cancer was the 
fourth most common cancer form in 
males after prostate, lung and uri-
nary tract cancers, with an age-
adjusted incidence rate of 13.4 per 
100 000 person-years. Rectal and 
anal cancer showed an incidence of 
10.9/ 100 000 in males and pre-
sented as the sixth most common 
cancer form. Similarly in females for 
the same period, colon cancer was 
the third most common cancer after 
breast and uterus cancers with an 
age-adjusted incidence rate of 12.0 
per 100 000 person-years. Rectal 
and anal cancer in females ranked 
ninth with an incidence of 6.8/ 100 
000 (Finnish Cancer Registry, 2003).  
 
However, in developed countries the 
age-adjusted mortality from colorec-
tal cancer in males and females was 
17.4/ 100 000 and 12.3/ 100 000 
respectively (International Agency 
for Research on Cancer, 2001). In 
Finland in 1999, colon cancer was 
the fifth most common cause of can-
cer related deaths, while rectal and 
anal cancer the seventh most com-
mon in males with mortalities of 6.5 
and 5.6 per 100 000 respectively 
(Finnish Cancer Registry, 2003). In 
females, colon cancer ranked fourth, 
while rectal and anal cancer were 
eighth with mortalities of 4.7 and 
3.0/ 100 000, respectively (Finnish 
Cancer Registry, 2003). The pre-
dicted five-year survival in the last 
five years has been 57% for colon 
cancer and 53% for rectal and anal 
cancer (Finnish Cancer Registry, 
2003). 
 
Established risk factors for colorectal 
cancer are inflammatory bowel dis-
ease, adenomas and polyps, inher-
ited disorders such as familial ade-
nomatous polyposis and hereditary 
non-polyposis colorectal cancer, as 
well as dietary factors (Potter et al., 
1993; Wilmink, 1997). 
 
Staging of colorectal cancer 
Tumour stage is generally considered 
to be the strongest prognostic factor 
in colorectal cancer (Gospodarowicz 
et al., 2001). Stage of the tumour in 
colorectal cancer is commonly de-
termined either according to the 
modified Dukes’ classification (ACPS 
system) (Davis et al., 1984) or the 
UICC (International Union Against 
Cancer) TNM-classification (Sobin & 
Wittekind, 2002), which are com-
pared in table 2. The Dukes’ classifi-
cation is generally the staging sys-
tem for colorectal cancer in Finland. 
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Table 2. Modified Dukes’ classification of colorectal cancer compared to TNM-stage (Sobin & Wit-
tekind, 2002). 
 Dukes’ classification (Davis et al., 1984) TNM stage (UICC 2002) (Sobin & Wit-
tekind, 2002) 
A vs. I Tumour in bowel wall not extending beyond 
muscularis propria 
Tumour invades submucosa (T1) or 
muscularis propria (T2) 
T1-2, N0, M0 
B vs. II Tumour extends beyond muscularis propria 
directly into adjacent tissues or organs 
Tumour invades into subserosa or non-
peritonealized pericolic or perirectal tissues 
(T3), or invades directly other organs or 
structures, or perforates visceral perito-
neum (T4) 
T3-4, N0, M0  
C vs. III Lymph node metastasis Regional lymph node metastasis (≤ 3 N1, ≥ 
4 N2) 
T1-4, N1-2, M0 
D vs. IV Any cancer remaining locally or at a dis-
tance after treatment 
Distant metastasis (M1) 
T1-4, N0-2, M1 
 
 
Diagnosis and treatment of colo-
rectal cancer 
The most important diagnostic 
method for colorectal cancer is 
colonoscopy, because apart from 
visualization of the tumour, it pro-
vides a definitive histological diagno-
sis from biopsies obtained during the 
procedure. Diagnostic methods for 
colorectal cancer also include barium 
enema; other radiological imaging 
techniques may serve as tools for 
evaluating the extent of disease. Dis-
tant metastasis may be detected 
with chest x-ray and abdominal US, 
or alternatively with computerized 
tomography (CT), and local invasion 
of rectal tumours may be evaluated 
with magnetic resonance imaging 
(MRI). 
 
The only fully curative treatment of 
colorectal cancer is radical surgical 
resection, which can be achieved 
particularly during the early stages of 
disease. This is reflected in the 
rather encouraging five-year survival 
rates for patients with Dukes’ A 
(about 90%) and B (about 65 to 
70%) colorectal cancer. The five-
year survival rate for Dukes’ C can-
cer is approximately 40 to 45%. 
Therefore, adjuvant treatment has 
been studied extensively particularly 
in Dukes’ B and C cancers where the 
rate of recurrence is clinically rele-
vant. The consensus statement of 
the National Cancer Institute from 
1990 stated that adjuvant chemo-
therapy should be the standard 
treatment for patients with node-
positive (Dukes’ C, stage III) re-
sected colon cancer (NIH consensus 
conference, 1990). A chemotherapy 
regimen consisting of 5-fluorouracil 
(5-FU) and leucovorin has been sug-
gested as the treatment of choice 
(Wolmark et al., 1993; Wolmark et 
al., 1999). However, the benefit of 
adjuvant chemotherapy is not yet 
established for patients with Dukes' 
B (or stage II) colorectal cancer (IM-
PACT B2, 1999; Mamounas et al., 
1999) 
 
Serum tumour markers in colorectal 
cancer 
Carcinoembryonic antigen (CEA) has 
been the most extensively studied 
and best documented tumour marker 
in the management of colorectal can-
cer. CEA is a cell membrane associ-
ated antigen originally identified in 
foetal colon and colon adenocarci-
noma in 1965 by Gold and Freedman 
(Gold & Freedman, 1965). CEA is a 
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glycoprotein belonging to the immu-
noglobulin superfamily (Paxton et al., 
1987). It has a molecular weight of 
about 200 kDa containing approxi-
mately 50% carbohydrate in complex 
oligosaccharide chains (Coligan et 
al., 1972; Westwood et al., 1974; 
Hammarström et al., 1975). 
CEA has been postulated to function 
as a cell adhesion molecule (Benchi-
mol et al., 1989; Oikawa et al., 
1992; Zhou et al., 1993). Although 
the sensitivity of CEA is insufficient 
for purposes of screening or primary 
diagnosis, several studies have 
shown CEA to have prognostic sig-
nificance in colorectal cancer 
(Wanebo et al., 1978; Blake et al., 
1982; Chu et al., 1991; Webb et al., 
1995; Harrison et al., 1997; Carri-
quiry & Piñeyro, 1999; Duffy, 2001). 
Based on these findings, recently 
published guidelines of the European 
Group on Tumour Markers (EGTM) 
proposed that CEA has clinical utility 
in prognosis and monitoring of colo-
rectal cancer (Duffy et al., 2003). 
This suggestion is in agreement with 
the consensus statements of the Col-
lege of American Pathologists from 
1999 and of the American Joint 
Committee on Cancer (Compton et 
al., 2000a; Compton et al., 2000b). 
 
Other potential serum markers 
widely studied in colorectal cancer 
include carbohydrate antigen CA 19-
9, which was initially characterized 
by a monoclonal mouse antibody ob-
tained by immunizing mice with a 
human colorectal carcinoma cell line 
SW 1116 (Koprowski et al., 1979). 
The antigen, recognized by the anti-
body of the same name, is an oligo-
saccharide corresponding to Lewisa 
blood group antigen, sialylated lacto-
N-fucopentaose II (Magnani et al., 
1982; Falk et al., 1983). The CA 19-
9 antigen is expressed in tissues 
predominantly as a monosialogan-
glioside and in serum it is associated 
with circulating mucins, high molecu-
lar weight glycoproteins rich in car-
bohydrate (Magnani et al., 1982; 
Magnani et al., 1983). However, 5% 
of the population lacks the Lewis 
gene encoding the fucosyltransferase 
enzyme that is required for CA 19-9 
production (Koprowski et al., 1982; 
Ritts et al., 1984). 
Although CA 19-9 is less sensitive 
than CEA in diagnosing colorectal 
cancer (Duffy, 1998), several studies 
have suggested that elevated levels 
correlate with adverse survival 
(Lindmark et al., 1995; Nakayama et 
al., 1997; Reiter et al., 1997b; Reiter 
et al., 2000). Moreover, a study with 
multivariate survival analysis indi-
cated that CA 19-9 provides inde-
pendent prognostic information in 
colorectal cancer (Filella et al., 
1992). The recent EGTM guidelines 
concluded that CA 19-9 may provide 
independent prognostic information, 
but conveys only little additive in-
formation to that of CEA in the fol-
low-up of colorectal cancer (Duffy et 
al., 2003). The American consensus 
statements declared that CA 19-9 is 
a potential prognostic factor in colo-
rectal cancer but at present has not 
been studied thoroughly enough 
(Compton et al., 2000a; Compton et 
al., 2000b). 
 
CA 242 is a sialylated antigen closely 
associated with CA 19-9 as it is 
found in serum on the same mucin 
complex (Baeckström et al., 1991; 
Johansson et al., 1991a; Johansson 
et al., 1991b; Nilsson et al., 1992). 
CA 242 is defined by a mouse mono-
clonal antibody (C242) that was 
raised against a human colorectal 
carcinoma cell line COLO 205 (Lind-
holm et al., 1983). Several studies 
have indicated that CA 242 provides 
independent prognostic information 
complementing CEA in the manage-
ment of colorectal cancer (Nilsson et 
al., 1992; Hall et al., 1994; Carpe-
lan-Holmström et al., 1996a; Carpe-
lan-Holmström et al., 1996b; Carpe-
lan-Holmström et al., 1996c; Hashol-
zner et al., 1999). 
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Tissue polypeptide antigen (TPA) and 
specific tissue polypeptide antigen) 
(TPS) are proteins associated with 
cytokeratins 8, 18 and 19, and are 
produced by rapidly growing tissues 
such as placenta and malignancies 
(Björklund & Björklund, 1957; Björk-
lund & Björklund, 1983; Bonfrer et 
al., 1994; Sundström & Stigbrand, 
1994). TPA and TPS have been 
shown to correlate with aggressive 
disease and to convey prognostic 
information (Lindmark et al., 1995; 
Carpelan-Holmström et al., 1996a; 
Lindmark et al., 1996). 
Tissue inhibitor of metalloproteinase-
1 (TIMP-1) is a glycoprotein involved 
in inhibiting metalloproteinase activ-
ity, stimulating cell growth and inhib-
iting apoptosis (Chambers & Matri-
sian, 1997). Furthermore, TIMP-1 
has also been suggested to predict 
poor outcome in colorectal cancer 
(Holten-Andersen et al., 2000). 
More recently the EGTM guidelines 
on the serum tumour markers CA 
242, TPA, TPS, and TIMP-1 con-
cluded that they seem to convey in-
dependent prognostic information, 
but sufficient data is currently lack-
ing to recommend their routine use 
for prognostic evaluation and moni-
toring of colorectal cancer (Duffy et 
al., 2003). 
 
CA 72-4 antigen (also called tumour 
associated glycoprotein 72, TAG-72) 
is a mucin-like glycoprotein defined 
by a monoclonal antibody B72.3 ob-
tained by immunization with a he-
patic metastasis cell line of breast 
carcinoma (Colcher et al., 1981; 
Johnson et al., 1986). In colorectal 
cancer, elevated CA 72-4 in serum 
has been suggested to correlate with 
adverse survival and to supplement 
CEA in detecting recurrence of the 
disease (Guadagni et al., 1993; 
Lindmark et al., 1996). The American 
consensus statements have proposed 
that CA 72-4 is a potential prognostic 
factor yet lacking sufficient evidence 
in colorectal cancer (Compton et al., 
2000a; Compton et al., 2000b).  
 
Other prognostic factors in colorec-
tal cancer 
Prognostic factors could serve as 
tools in clinical practice to reliably 
identify those patients with a low or 
high risk of recurrence, thus helping 
in the prospective selection of ther-
apy for an individual patient: pa-
tients with only a low risk could be 
spared the hardship of adjuvant 
treatment, whereas those patients 
with a significant risk of recurrence 
could be treated efficiently. However, 
it is unclear whether distinct prog-
nostic factors also have predictive 
value in correlating with the re-
sponse to treatment. 
 
The consensus statement of the Col-
lege of American Pathologists from 
1999 and the American Joint Com-
mittee on Cancer defined four cate-
gories of prognostic factors: (I) fac-
tors with definitely proven prognostic 
importance; (II) extensively studied 
factors with repeatedly shown prog-
nostic value but lacking the statistical 
data to be included in the first cate-
gory; (III) putative factors which 
have not yet been sufficiently stud-
ied; (IV) well studied factors with no 
prognostic value (Compton et al., 
2000a; Compton et al., 2000b). 
 
Prognostic factors for each category 
according to the consensus state-
ments are outlined below.  
Category I factors included the 
pathologically assessed local extent 
of the tumour (pT), regional lymph 
node metastasis (pN), blood or lym-
phatic vessel invasion, residual tu-
mour after surgery (R classification), 
and preoperative CEA. The recent 
American consensus statements con-
cluded that an elevated preoperative 
serum level of CEA has been shown 
to have prognostic significance inde-
pendent of tumour stage, and fur-
thermore should be included in the 
staging system reported as either CX 
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(CEA level not assessed), C0 (CEA < 
5 µg/L), or C1 (CEA ≥ 5 µg/L).  
 
Category II factors comprised tu-
mour grade, radial margin status, 
TNM-classification of the tumour af-
ter neoadjuvant treatment, histologi-
cal type and features associated with 
microsatellite instability, high degree 
of microsatellite instability, certain 
chromosomal alterations, and tu-
mour border configuration. 
 
Category III factors included DNA 
content, perineural invasion, mi-
crovessel density, peritumoural fibro-
sis and inflammatory response, focal 
neuroendocrine differentiation, nu-
cleolar organizing regions, prolifera-
tion indices, and tumour cell associ-
ated proteins and carbohydrates 
such as tumour markers CA 19-9 and 
CA 72-4. In addition, tumour tissue 
molecular markers, such as K-ras, 
p27, p21, Bcl-2, p53, TGF-β1, VEGF, 
and CD44, were included in this 
category. Molecular markers have 
provided promising preliminary re-
sults on diagnostic, prognostic or 
predictive aspects in management of 
colorectal cancer, but the data to 
date remains insufficient for making 
recommendations for their use in 
clinical practice. 
 
Category IV comprised those factors 
with no prognostic value in colorectal 
cancer such as tumour size and gross 
tumour configuration. 
 
Gastric cancer 
Epidemiology of gastric cancer 
Gastric cancer is the second most 
common digestive tract malignancy 
after colorectal cancer. In 2000 its 
age-adjusted incidence was 24.6/ 
100 000 in males and 11.0/ 100 000 
in females from developed countries 
(International Agency for Research 
on Cancer, 2001). In Finland, the 
incidence has diminished dramati-
cally in the last five decades. In 
2000, gastric cancer was the eighth 
most common cancer in males and 
the eleventh most common in fe-
males. The age-adjusted incidence 
rate was 9.9/ 100 000 in males and 
5.7/ 100 000 in females, whereas 
during the 1950's the incidence was 
about six times higher for both sexes 
(Finnish Cancer Registry, 2003).  
 
Although the incidence has been de-
creasing, gastric cancer continues to 
be a clinically important cause of 
morbidity and mortality with rather 
poor outcome. In 2000 gastric cancer 
was the leading cause of cancer-
related death of digestive tract ma-
lignancies worldwide accounting for 
more than 640,000 deaths. In devel-
oped countries, its age-adjusted 
mortality in males and females was 
16.2/ 100 000 and 7.7/ 100 000 (In-
ternational Agency for Research on 
Cancer, 2001). In Finland in 1999, 
the age-adjusted mortality of gastric 
cancer was 8.1/ 100 000 in males, 
being the third most common cause 
of cancer death after lung and pros-
tate cancers. In females the mortal-
ity was 3.6/ 100 000, being the sixth 
most common cause of cancer death 
after cancers of breast, lung, pan-
creas, colon, and ovaries. The pre-
dicted 5-year relative survival rate in 
the last five years has been 26% 
(Finnish Cancer Registry, 2003).  
 
Established risk factors for gastric 
cancer are helicobacter pylori infec-
tion, atrophic gastritis and pernicious 
anaemia, intestinal metaplasia, pre-
vious gastric surgery, gastric ulcers, 
ionizing radiation, certain dietary as 
well as hereditary factors (Kelley & 
Duggan, 2003). 
 
Staging of gastric cancer 
One of the most important prognos-
tic factors influencing the survival of 
patients with gastric cancer has been 
the anatomic extent of the disease 
represented by tumour stage (Go-
spodarowicz et al., 2001). The stage 
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of gastric tumours is commonly de-
termined according to the UICC TNM-
classification, which is described in 
table 3 according to the two latest 
editions of UICC TNM-classification 
(Sobin & Wittekind, 1997; Sobin & 
Wittekind, 2002). 
 
Table 3. TNM stage of gastric cancer according to UICC 1997 and 2002 (Sobin & Wittekind, 1997; 
Sobin & Wittekind, 2002). 
Stage I T1, N0-1, M0 
T2, N0, M0 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria or subserosa 
N1 Metastasis in 1 to 6 regional lymph nodes 
Stage II T1, N2, M0 
T2, N1, M0 
T3, N0, M0 
T3 Tumour penetrates serosa 
N2 Metastasis in 7 to 15 regional lymph nodes 
Stage III T2-3, N2, M0 
T3, N1, M0 
T4, N0, M0 
T4 Tumour invades adjacent structures 
Stage IV T4, N1-3, M0 
T1-3, N3, M0 
T1-4, N0-3, M1 
N3 Metastasis in more than 15 regional lymph nodes 
M1 Distant metastasis 
 
 
Histological types of gastric cancer 
The histological type of the tumour is 
regarded as an essential prognostic 
factor in gastric cancer (Gospo-
darowicz et al., 2001). Several sys-
tems exist for classification of the 
histological type. One of the most 
commonly applied is the Laurén clas-
sification, which distinguishes intes-
tinal adenocarcinoma from diffuse 
mucocellular type (Laurén, 1965). 
The intestinal carcinoma usually pre-
sents glandular structures with little 
or no mucus production, whereas 
diffuse type tumour cells are scat-
tered as solitary cells or as cell clus-
ters with mucus secretion in nearly 
all of the tumour cells. The intestinal 
type tumours typically spread to a 
distinctly defined area, while the dif-
fuse type forms less defined tu-
mours.  
 
The WHO classification differentiates 
the histological type of gastric can-
cers into adenocarcinomas, 
adenosquamous carcinomas and un-
differentiated carcinomas (Oota & 
Sobin, 1977). Adenocarcinomas are 
tumours of glandular epithelium, 
adenosquamous carcinomas show 
both adenocarcinomatous and 
squamous elements in an individual 
tumour, whereas undifferentiated 
tumours are epithelial tumours with 
no definite features of any specific 
line of differentiation. In addition, the 
WHO classification further divides the 
histology of adenocarcinomas into 
subgroups of papillary, tubular, 
mucinous, or signet-ring cell types, 
or alternatively by grade into well, 
moderately or poorly differentiated 
carcinomas.  
 
According to the Ming classification 
gastric carcinomas are categorized 
either as expanding or infiltrative 
type (Ming, 1977). The expanding 
tumour seems to grow by forming 
discrete tumour nodules with glandu-
lar structures being common. The 
growth pattern of the infiltrative tu-
mour is more diffuse with individually 
penetrating tumour cells often ac-
companied by mucus production. The 
classification criteria of expanding 
and infiltrative tumours correspond 
closely to the Laurén classification of 
intestinal and diffuse types (Ming, 
1977). 
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Diagnosis and treatment of gastric 
cancer 
The most important diagnostic pro-
cedure is gastroscopy, which pro-
vides the possibility of obtaining bi-
opsies for definitive histological diag-
nosis. Radiological imaging tech-
niques (US, CT, MRI) are mainly ap-
plied for assessing the spread of the 
disease. 
 
The only curative treatment for gas-
tric cancer is radical surgical resec-
tion. Most current adjuvant treat-
ments have provided only some im-
provement in survival. Adjuvant 
chemotherapy has been evaluated in 
meta-analyses: Hermans et al. ob-
served no benefit in survival (Her-
mans et al., 1993), whereas Earle et 
al. and Mari et al. detected some im-
provement in survival in favour of 
adjuvant chemotherapy compared to 
surgery alone (Earle & Maroun, 
1999; Mari et al., 2000). Adjuvant 
radiotherapy alone has been shown 
to have no positive effect on out-
come of patients with gastric cancer 
(Hallissey et al., 1994). Adjuvant 
chemoradiotherapy with 5-FU and 
leucovorin, however, has been sug-
gested to convey significant im-
provement on outcome of patients 
with resectable gastric cancer (Mac-
donald et al., 2001). According to a 
recent Canadian practice guideline, 
the adjuvant treatment of choice is 
chemoradiotherapy based on 5-FU 
and leucovorin (Earle et al., 2002).  
 
Serum tumour markers in gastric 
cancer 
The most widely studied tumour 
markers in gastric cancer have been 
CEA, CA 19-9 and CA 72-4. Of these 
three, CA 72-4 has been proposed to 
be the most sensitive and specific 
(Guadagni et al., 1992). However, 
multivariate survival analysis shows 
conflicting data for their prognostic 
value and hitherto no tumour mark-
ers have emerged into clinical prac-
tice for the diagnosis and manage-
ment of gastric cancer. Several stud-
ies have demonstrated CEA or CA 
19-9 to have independent prognostic 
value (Maehara et al., 1994; Nakane 
et al., 1994; Kodera et al., 1996; 
Reiter et al., 1997a; Tachibana et al., 
1998; Tocchi et al., 1998; Ishigami 
et al., 2001), but in other studies no 
significant correlation with survival 
was observed (Kodera et al., 1996; 
Webb et al., 1996; Gaspar et al., 
2001; Ishigami et al., 2001; Lai et 
al., 2002; Nakagoe et al., 2002). 
Furthermore, CA 72-4 has been sug-
gested to be a stronger prognostic 
factor than CEA and CA 19-9 in gas-
tric cancer (Gaspar et al., 2001), 
whereas in other studies CA 72-4 has 
lacked independent prognostic sig-
nificance (Tocchi et al., 1998; Lai et 
al., 2002). In addition the sialyl Tn 
antigen (α2,6-N-
acetylgalactosamine, STN), a less 
established gastrointestinal marker, 
has been proposed as a prognostic 
marker in gastric cancer (Takahashi 
et al., 1994; Nakagoe et al., 2001). 
The carbohydrate associated sialyl Tn 
antigen is found on abnormal mucin-
like glycoproteins (Hakomori, 1989). 
 
Other prognostic factors in gastric 
cancer 
The established prognostic factors 
influencing survival of patients with 
gastric cancer are histological type of 
the tumour, anatomic extent of the 
disease reflected by the TNM-
classification and stage, as well as 
the possibility of curative surgical 
resection (Gospodarowicz et al., 
2001). In addition, a recent report 
suggested that the stage and eosi-
nophilic infiltration of tumour stroma 
are independent prognostic factors in 
potentially curable gastric cancer 
(Cuschieri et al., 2002). 
 
Similar to colorectal cancer, various 
tissue molecular markers have also 
been studied in gastric cancer. Some 
adhesion molecules and matrix met-
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alloproteinases may be considered as 
new and promising prognostic factors 
(Gospodarowicz et al., 2001), al-
though the data has not been con-
clusive enough to merit a citation in 
international guidelines for clinical 
practice (EGTM, 1999; Fleisher et al., 
2002). 
 
Pancreatic cancer 
Epidemiology of pancreatic cancer 
Despite recent advances in the diag-
nosis and treatment of cancer, pan-
creatic cancer retains a rather dismal 
prognosis. In the last 20 years, its 
age-adjusted incidence in Finland has 
been 5-10/ 100 000 with nearly 
100% mortality (Finnish Cancer Reg-
istry, 2003). In 1999 pancreatic can-
cer was the fourth leading cause of 
cancer-related deaths in males, and 
the third in females. The predicted 5-
year relative survival rate of pancre-
atic cancer, including both exocrine 
and endocrine malignancies, is only 
2% (Finnish Cancer Registry, 2003), 
and of exocrine malignancies less 
than 0.5% (Gudjonsson, 1987; 
Alanen & Joensuu, 1993).  
 
Worldwide in the year 2000, pancre-
atic cancer accounted for more than 
210,000 deaths, and in developed 
countries its age-adjusted incidence 
and mortality were 7.8/ 100 000 and 
7.7/ 100 000 in males, and 5.1/ 100 
000 and 5.1/ 100 000 in females, 
respectively (International Agency 
for Research on Cancer, 2001). In 
developed countries, pancreatic can-
cer was the third most common di-
gestive tract malignancy after colo-
rectal and gastric cancers and it was 
also the third leading cause of cancer 
death from digestive tract malignan-
cies (International Agency for Re-
search on Cancer, 2001). 
 
The aetiology of pancreatic cancer is 
unknown, but generally accepted risk 
factors are chronic and hereditary 
pancreatitis, diabetes, some heredi-
tary syndromes, cigarette smoking 
and some dietary factors, as well as 
exposure to certain carcinogens (Di-
Magno et al., 1999). 
 
Staging of pancreatic cancer 
The staging of pancreatic tumours is 
commonly assessed according to the 
UICC TNM-classification. The staging 
criteria of the UICC TNM-system has 
varied markedly for pancreatic can-
cer particularly in the last three edi-
tions (Hermanek & Sobin, 1987; So-
bin & Wittekind, 1997; Sobin & Wit-
tekind, 2002); table 4 outlines the 
two latest editions. This variation 
reflects the degree of interest and 
research as well as the growing 
knowledge of factors influencing 
prognosis of patients with pancreatic 
cancer. Accordingly, tumour-related 
factors, such as stage of the disease 
at the time of diagnosis, and thereby 
the possibility of curative resection, 
have been the most important prog-
nostic factors in pancreatic cancer 
(Gospodarowicz et al., 2001).  
 
Table 4. Comparison of TNM stage according to UICC 1997 and 2002 in pancreatic cancer (Sobin & 
Wittekind, 1997; Sobin & Wittekind, 2002). 
 TNM stage UICC 1997 (Sobin & Wittekind, 
1997) 
TNM stage UICC 2002 (Sobin & Wittekind, 
2002) 
Stage I T1-2, N0, M0 
 
T1 Tumour limited to pancreas, ≤ 2 cm 
T2 Tumour limited to pancreas, > 2 cm 
T1-2, N0, M0 
 
T1 Tumour limited to pancreas, ≤ 2 cm 
T2 Tumour limited to pancreas, > 2 cm 
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Stage II T3, N0, M0  
 
 
T3 Tumour extends directly into duode-
num, bile duct or peripancreatic tissues 
T3, N0, M0 
T1-3, N1, M0 
 
T3 Tumour extends beyond pancreas 
without involvement of coeliac axis or su-
perior mesenteric artery 
N1 Regional lymph node metastasis 
Stage III T1-3, N1, M0 
 
N1 Regional lymph node metastasis 
T4, N0-1, M0 
 
T4 Tumour involves coeliac axis or supe-
rior mesenteric artery 
Stage IV T4, N0-1, M0 
T1-4, N0-1, M1 
 
T4 Tumour extends directly into stomach, 
spleen, colon, adjacent large vessels 
M1 Distant metastasis 
T1-4, N0-1, M1 
 
 
M1 Distant metastasis 
 
 
Diagnosis and treatment of pan-
creatic cancer 
The diagnosis of pancreatic cancer at 
early stages of the disease is prob-
lematic due to the lack of specific 
symptoms. This is compounded by a 
tendency for early metastasis to re-
gional lymph nodes and liver, which 
is an unfortunate characteristic fea-
ture of pancreatic cancer. Conse-
quently, a majority of cases are di-
agnosed at advanced stages of the 
disease, which in turn yields the 
over-all dismal prognosis. Various 
radiological imaging techniques (US, 
CT, MRI, endoscopic US) serve as 
diagnostic methods for pancreatic 
cancer. Endoscopic retrograde 
cholangiopancreaticography (ERCP) 
may also provide useful diagnostic 
information on tumours of the pan-
creas.  
 
The only treatment with impact on 
survival in pancreatic cancer is radi-
cal surgical resection. However, the 
patient outcome remains poor even 
after a successful apparently curative 
resection. Therefore, adjuvant treat-
ments have been studied in the hope 
of improving survival. Adjuvant 
chemotherapy regimens have been 
based on 5-FU or gemcitabine; the 
latter has been proposed to be the 
more effective of the two (Rothen-
berg et al., 1996; Burris et al., 
1997). Nevertheless, both regimens 
have shown only minimal improve-
ment in long-term survival in ad-
vanced disease (Cullinan et al., 
1990; Rothenberg et al., 1996; 
Burris et al., 1997). In addition, the 
radiosensitization properties of che-
motherapeutic agents have also been 
under investigation. A small study 
with 5-FU based chemoradiation ad-
juvant treatment demonstrated sig-
nificant improvement in survival 
(Kalser & Ellenberg, 1985). However, 
another somewhat larger trial con-
cluded that no demonstrable benefit 
arose from 5-FU based chemoradia-
tion (Klinkenbijl et al., 1999). Fur-
thermore, apart from adjuvant che-
motherapy and chemoradiation 
treatment, also chemoimmunother-
apy has been evaluated. The addition 
of interleukin-2 to the chemotherapy 
regimen was suggested to convey a 
significant positive impact on out-
come (Lygidakis et al., 2002). The 
adjuvant treatment modalities con-
tinue to be of considerable scientific 
interest with several ongoing ran-
domised trials. 
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Serum tumour markers in pancre-
atic cancer 
In pancreatic cancer, the role of tu-
mour markers is not established in 
clinical practice. However, CA 19-9 
has been the most extensively stud-
ied tumour marker and is suggested 
to be the "gold standard marker" in 
diagnosis and follow-up of pancreatic 
cancer (EGTM, 1999). The prognostic 
value of tumour markers CA 19-9 
and CEA is well documented, and 
both of them have been associated 
with adverse outcome (Kalser et al., 
1978; Glenn et al., 1988; Taylor et 
al., 1992; Tian et al., 1992; Lundin 
et al., 1994; Yasue et al., 1994; Gat-
tani et al., 1996; Nakao et al., 1998; 
Safi et al., 1998; Takeuchi et al., 
1998). Other possibly useful, but less 
established markers include CA 195 
and CA 242, which have been shown 
to predict poor prognosis in pancre-
atic cancer (Taylor et al., 1992; 
Lundin et al., 1995). CA 195 is a car-
bohydrate antigen recognized by a 
monoclonal mouse antibody raised 
against a human hepatic metastasis 
cell line of colon cancer; the antibody 
reacts with sialylated Lewisa and the 
Lewisb antigens (Fukuta et al., 
1987). 
 
Other prognostic factors in pan-
creatic cancer 
The established prognostic factors in 
pancreatic cancer are tumour-related 
factors, such as the anatomic extent 
of the disease represented by TNM 
classification and stage, as well as 
the possibility of curative surgical 
resection (Gospodarowicz et al., 
2001).  
 
Tissue molecular markers such as 
tumour suppressor genes (p53, p16, 
DPC4, Bcl-2), proto-oncogenes (Ki-
67), oncogenes (K-ras) and growth 
factors (VEGF, EGF/ EGFR, TGFβ, 
FDG-PET) have been proposed as 
new and promising prognostic factors 
(Gospodarowicz et al., 2001). How-
ever, further studies are needed to 
establish their true value and role in 
clinical practice. 
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AIMS OF THE STUDY 
The aims of the present study were threefold: 
 
 
1. To investigate the tissue expression of hCGβ in various digestive tract malig-
nancies and benign pancreatic and biliary tissues by immunohistochemistry. The 
purpose was also to verify the specificity of the staining and to compare the re-
sults with those obtained from a widely used commercial polyclonal antibody 
against hCG (I). 
 
 
2. To assess the expression of hCGβ in serum from patients with various diges-
tive tract malignancies and benign conditions and to compare the diagnostic 
value of serum hCGβ with two commonly applied markers for gastrointestinal 
malignancies, CEA and CA 19-9. In addition, the aim was to evaluate the use of 
an algorithm derived from logistic regression analysis as a diagnostic test (II). 
 
 
3. To elucidate the preoperative hCGβ and its relationship with prognosis and to 
compare it with more established serum tumour markers CEA, CA 19-9, CA 242, 
and CA 72-4 in patients with colorectal, gastric, and pancreatic cancer, three of 
the most common digestive tract cancer forms in developed countries (III-V). 
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MATERIALS AND METHODS 
Patients and samples 
Tissue samples (I) 
Formalin-fixed and paraffin-
embedded tissue sections from diag-
nostic biopsies or surgically removed 
tissue samples were obtained from 
143 patients treated at the Depart-
ment of Surgery, Helsinki University 
Central Hospital; 107 samples were 
from patients with various digestive 
tract malignancies and 36 samples 
from patients with pancreatitis, nor-
mal pancreas, and benign biliary 
ducts. 
 
Serum samples (II-V) 
Preoperative serum samples were 
obtained from patients treated at the 
Department of Surgery, Helsinki Uni-
versity Central Hospital. The samples 
were taken within 30 days prior to 
surgery, or if the patient was not op-
erated on, within 30 days prior to 
histo- or cytological confirmation of 
the diagnosis. Serum samples were 
stored at -20°C or at -80°C prior to 
analysis.  
Samples included serum from 142 
patients with different gastrointesti-
nal malignancies and 178 with vari-
ous benign digestive tract diseases 
(II); from 204 patients with primary 
colorectal cancer (III); from 146 pa-
tients with primary gastric cancer 
(IV); and from 160 patients with 
primary ductal adenocarcinoma of 
the pancreas (V). The diagnosis of 
malignancy was verified either his-
tologically from biopsies or surgical 
specimens, or cytologically from fine 
needle biopsies. Tumour stage was 
determined according to the modified 
Dukes’ classification for colorectal 
(Davis et al., 1984) (II, III) or ac-
cording to the 1997 UICC TNM-
classification for the other cancers 
(Sobin & Wittekind, 1997) (II, IV, V) 
based on patient data on radiological 
findings, clinical findings at opera-
tion, and histology. Table 5 shows 
clinicopathological characteristics of 
patients with colorectal, gastric, or 
pancreatic cancer (III-V).  
Patients with meta- or synchronous 
malignancies, and patients who had 
received neoadjuvant treatment were 
excluded from the studies. The clini-
cal data and survival and cause of 
death data were obtained from pa-
tient records, the Population Register 
Centre of Finland, and the Statistics 
Finland.  
The hospital ethics committee has 
approved the study. 
 
 
Table 5. Clinicopathological characteristics of 204 patients with colorectal (III), 146 with gastric (IV), 
and 160 with pancreatic cancer (V) (NA= Not available). 
Variables Colorectal cancer 
n=204
Gastric cancer 
n=146
Pancreatic cancer 
n=160
Male 108 (53%) 73 (50%) 79 (49%) 
Female 96 (47%) 73 (50%) 81 (51%) 
Age 22.7-92.5 years,  
median 66.6 years
31.6- 88.4 years, 
median 63.8 years
40.7-87.5 years,  
median 63.8 years
Stage 31 (15%) Dukes A 29 (20%) Stage I 10 (6%) Stage I 
 70 (34%) Dukes B 11 (8%) Stage II 25 (16%) Stage II 
 49 (24%) Dukes C 42 (29%) Stage III 24 (15%) Stage III 
 54 (26%) Dukes D 64 (44%) Stage IV 101 (63%) Stage IV 
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Resected for cure 150 (74%) 78 (53%) 29 (18%) 
Tumour location 102 (50%) Colon 16 (11%) Cardia or 
fundus
130 (81%) Caput 
 102 (50%) Rectum 68 (47%) Corpus or 
angulus
26 (16%) Corpus or 
cauda 
  41 (28%) Antrum 4 (3%) Whole pancreas
  18 (12%) Whole  
stomach
 
  3 (2%) Amputated 
stomach
 
Tumour histology 190 (93%) Adenocarci-
noma 
57 (39%) Intestinal type 160 (100%) Ductal ade-
nocarcinoma 
 14 (7%) Mucinous car-
cinoma 
88 (60%) Diffuse type  
  1 (1%) NA  
Tumour size NA 45 (31%) <5cm 50 (31%) ≤3cm 
  38 (26%) ≥5cm, <10cm 69 (43%) >3cm, ≤6cm 
  54 (37%) ≥10cm 32 (20%) >6cm 
  9 (6%) NA 9 (6%) NA 
 
 
Methods 
Immunohistochemical staining pro-
cedure (I) 
For the immunohistochemical stain-
ing of hCGβ, two antibodies were 
compared, a MAb (clone 9C11) 
(Alfthan et al., 1988), and a com-
mercial polyclonal antibody (PAb) 
(rabbit anti-hCG, code no. A 231, 
Dakopatts, Glostrup, Denmark). Be-
nign tissue sections were stained 
with three additional in-house anti-
hCGβ MAbs (clones 6G5, 6E11, and 
7E3, characterized and produced in 
the laboratory of Ulf-Håkan Stenman 
and Henrik Alfthan). MAbs 9C11, 
6E11, and 7E3 react specifically with 
the free β-subunit, whereas MAb 6G5 
and the polyclonal antibody also re-
act with intact hCG (data not 
shown). In addition, the polyclonal 
antibody has been reported to cross-
react with LHβ (Morrish et al., 1987). 
Paraffin sections mounted on 3-
aminopropyl-triethoxy-silane coated 
slides (APES) (Sigma, St. Louis, MO, 
USA) were deparaffinized with xylene 
and rehydrated in graded concentra-
tions of ethanol to distilled water. 
The sections were pre-treated with 
0.5% trypsin (Difco Laboratories, 
Detroit, MI, USA), followed by incu-
bation with 0.5% hydrogen peroxide 
in methanol to block endogenous 
peroxidase. To reduce non-specific 
staining, the slides were pre-
incubated with normal horse serum 
(for staining with MAbs) or with nor-
mal goat serum (for PAb) before 
staining (dilutions 1:67, Elite ABC 
Kit, Vectastain, Vector Laboratories, 
Burlingame, CA, USA). The sections 
were incubated with the primary an-
tibodies overnight at room tempera-
ture with the following dilutions: 
1:1000 for MAbs 9C11 and 6G5, and 
1:500 for MAbs 6E11, 7E3 and the 
polyclonal antibody.  
Bound antibody was visualized with 
the ABC immunoperoxidase tech-
nique (avidin-biotin complex) (Elite 
ABC Kit). The sections were first in-
cubated with biotinylated second 
layer antibody and then with peroxi-
dase-labelled avidin-biotin complex. 
Visualization of peroxidase activity 
was performed with 3-amino-9-
ethyl-carbazole (Sigma, St. Louis, 
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MO, USA) in acetate buffer contain-
ing 0.03% hydrogen peroxide. The 
sections were counterstained in 
Mayer’s haematoxylin and mounted 
in aqueous mounting media 
(Aquamount, BDH, Poole, UK). 
Sections of normal human placenta 
or hCG positive ovarian carcinoma 
were included as positive controls. 
The negative controls included sub-
stitution of the primary antibody with 
PBS (phosphate-buffered saline, pH 
7.2) or with a MAb against muscle 
actin recognizing actin filaments of 
skeletal, cardiac, and smooth muscle 
(dilution 1:50, mouse IgG1 anti-
muscle actin, clone HHF35, Enzo Di-
agnostics, Farmingdale, NY, USA).  
To establish the specificity of the 
immunostaining, the antibody was 
absorbed by blocking its binding sites 
with exogenous hCG. MAb 6G5 was 
incubated with a 10-fold molar ex-
cess of hCG purified from a partially 
purified hCG preparation (Pregnyl®, 
Organon, Oss, The Netherlands). The 
mixture was separated by gel filtra-
tion and fractions of high molecular 
weight (>100 kDa), corresponding to 
the antibody-hCG complex, were col-
lected and used in immunohisto-
chemistry to replace the primary an-
tibody at a final dilution of 1:1000. 
Red cytoplasmic staining with blue 
counterstaining of the nuclei was 
considered positive. The staining re-
sult was graded on a scale of 0 to 3 
based on the percentage of positive 
cells: absent (0) <1%, weak (1) 1-
10%, moderate (2) 11-30%, and 
strong (3) > 30%. The intensity of 
the stain had no influence on the 
score.  
 
Serum Assays (II-V) 
In the present study, the measure-
ment of hCGβ in serum was per-
formed by a highly sensitive non-
commercial time-resolved im-
munofluorometric assay (IFMA) util-
izing monoclonal antibodies specific 
for the free β-subunit of hCG (Alfthan 
et al., 1988). The majority of pa-
tients with non-trophoblastic cancer 
have a very low concentration of 
hCGβ in serum. However, the com-
mercial hCGβ assays are mainly de-
signed for screening and manage-
ment of pregnancy related disorders 
when the concentration of hCGβ is 
usually relatively high. The detection 
limit of the IFMA is 0.27 pmol/L with 
an inter-assay coefficient of variation 
(CV) of 10.7% at the concentration 
of 97 pmol/L (Alfthan et al., 1992a). 
The applied cut-off value for hCGβ 
(based on the 97.5 percentile of 
healthy blood donors) was 2 pmol/L 
(Alfthan et al., 1992a). 
 
The serum levels of CEA, CA 19-9, 
CA 242, and CA 72-4 were measured 
by commercial assays. The serum 
levels of CEA and CA 19-9 (II) were 
measured on the Bayer Immuno 1 
system (Bayer, Tarrytown, New York, 
USA). The applied cut-off values 
were 5 µg/L for CEA and 35 kU/L for 
CA 19-9 (cut-off values recom-
mended by the manufacturer). CEA 
(III-V) was measured by a time-
resolved IFMA (AutoDELFIA®, Wal-
lac, Turku, Finland). The detection 
limit of the assay is 0.2 µg/L and the 
inter-assay CV is <3% in the concen-
tration range 3-90 µg/L (total CV 
<4%). CA 19-9 and CA 72-4 (III-V) 
were quantified by immunoenzy-
mometric assays (Immuno1®, 
Bayer, Tarrytown, NY). Detection 
limits of the assays are 0.8 kU/L and 
0.3 kU/L, respectively. The total CV 
for CA 19-9 is <3% in the concentra-
tion range 15-230 kU/L and for CA 
72-4 <6% in the range 6-51 kU/L. 
CA 242 (III-V) was measured by a 
manual immunoenzymometric assay 
(CanAg Diagnostics, Gothenburg, 
Sweden). The detection limit is 1 
kU/L and inter-assay CV is <7% in 
the concentration range 13-134 
kU/L. The applied cut-off values for 
the tumour markers (III-V) were 5 
µg/L for CEA, 37 kU/L for CA 19-9, 6 
kU/L for CA 72-4, and 20 kU/L for CA 
242. 
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Statistical analysis (II-V) 
The association between elevated 
tumour marker serum levels (serum 
value above the specified cut-off 
value) and tumour stage, size and 
location was assessed with the χ2-
test. The Mann-Whitney U-test was 
applied to determine the significance 
of the difference in tumour marker 
concentrations between the sexes, 
between malignant and benign dis-
ease groups (II), the colonic and rec-
tal tumours (III), the intestinal and 
diffuse histological type (Laurén clas-
sification) (IV), and between jaun-
diced and non-jaundiced patients 
(V). The correlations between serum 
levels of individual markers, as well 
as between marker levels and age, 
and between markers and other rou-
tine laboratory tests, were assessed 
by the Spearman Rank correlation 
test. 
 
The diagnostic accuracies of hCGβ, 
CEA and CA 19-9 were compared 
with McNemar’s test (II). Logistic 
regression (LR) analysis was applied 
to evaluate and compare the diag-
nostic information provided by the 
tumour markers and their combina-
tions (Hosmer & Lemeshow, 2000) 
(II). The LR model was established 
with hCGβ, CEA and CA 19-9 as pre-
dictor variables, while cancer status 
(malignant or benign disease) was 
the binary outcome variable. Several 
transformations of the predictor vari-
ables were tested, and the best 
model was achieved with marker 
values as continuous variables with 
logarithmic transformation of the se-
rum concentrations. The best fit of 
the model with different marker 
combinations was assessed with 
Likelihood Ratio -test. The probability 
of cancer for each patient was calcu-
lated with the LR model, and it 
served as a diagnostic test. Receiver 
operating characteristic (ROC) curves 
were constructed and the differences 
in the area under the curve (AUC) 
values were determined between the 
tumour markers and the calculated 
probability of cancer (Hanley & 
McNeil, 1983).  
 
Life-tables were calculated (III-V) 
with the Kaplan-Meier method and 
the log-rank test was applied to test 
the significance of differences in sur-
vival between subgroups of patients. 
Patients alive at the end of the fol-
low-up period, patients lost to follow-
up due to emigration, and patients 
who died from unrelated causes were 
treated as censored cases. In addi-
tion, patients who died postopera-
tively (within 30 days from opera-
tion) were censored (III, IV).  
 
Multivariate survival analysis (III-V) 
was performed with the Cox propor-
tional hazards regression model. 
Clinical variables included as covari-
ates in the model were age, gender, 
stage, and tumour location. In addi-
tion, histological type of the tumour 
(III, IV), tumour size and curative 
resection (IV, V), and jaundice (V) 
were also included as covariates. The 
serum tumour marker levels of hCGβ 
and CEA, CA 19-9, CA 242 and CA 
72-4 were entered as continuous 
variables, and a logarithmic trans-
formation was applied on account of 
the non-Gaussian distribution of the 
marker values. For selection of vari-
ables, the multivariate Cox regres-
sion analysis was performed with 
both backward and forward stepwise 
procedure applying the likelihood 
ratio test with a limit of p= 0.05 for 
exclusion or inclusion of a variable. 
 
Statistical analyses were performed 
with StatView 5.0 (II) software (SAS 
Institute Inc., Cary, NC, USA) or with 
SPSS 10.07 (III) or 11.0.1(IV, V) 
software (SPSS Inc., Chicago, Illi-
nois, USA). 
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RESULTS 
Tissue expression of hCGβ in 
benign and malignant diges-
tive tract diseases (I) 
Differences in the tissue staining of 
hCGβ were observed both in benign 
and malignant samples between the 
MAb 9C11 and the polyclonal anti-
body (Dakopatts). Table 6 shows the 
distribution of hCGβ expression in 
malignant and benign gastrointesti-
nal tissues. Gastric and pancreatic 
carcinomas, and extrahepatic 
cholangiocarcinomas were most fre-
quently stained with MAb 9C11. With 
the PAb, positive staining was most 
frequent in small intestinal carci-
noids, small intestinal adenocarcino-
mas, oesophageal adenocarcinomas, 
and extrahepatic cholangiocarcino-
mas. Hepatocellular carcinomas, in-
trahepatic cholangiocarcinomas, and 
intestinal lymphomas were negative 
for hCGβ with both antibodies. 
 
Table 6. Frequency of immunohistochemical expression of hCGβ in malignant and benign gastrointes-
tinal tissues with two different antibodies (I). 
Malignancy n MAb 9C11 PAb Dakopatts 
Oral squamous cell carcinoma 7 14% 0% 
Oesophageal adenocarcinoma 9 11% 56% 
Oesophageal squamous cell carcinoma 10 0% 30% 
Gastric carcinoma 15 60% 40% 
Small intestinal adenocarcinoma 7 29% 57% 
Small intestinal carcinoid 10 20% 70% 
Colorectal carcinoma 13 15% 0% 
Pancreatic adenocarcinoma 9 56% 33% 
Hepatocellular carcinoma 9 0% 0% 
Intrahepatic cholangiocarcinoma 3 0% 0% 
Extrahepatic cholangiocarcinoma  11 36% 55% 
Intestinal lymphoma 4 0% 0% 
 107 24% 32% 
Benign disease n MAb 9C11 PAb Dakopatts 
Acute pancreatitis 8 63% 0% 
Chronic pancreatitis 10 40% 0% 
Normal pancreas 10 40% 0% 
Benign biliary tract 8 50% 0% 
 36 47% 0% 
 
 
The staining result of the benign 
pancreatic and biliary samples was 
verified by additional stainings with 
two MAbs (clones 6E11 and 7E3) 
specific for the free hCGβ and a MAb 
(clone 6G5) reacting with both the 
intact hCG and the free β subunit. 
The findings were analogous with the 
staining results of MAb 9C11. In ad-
dition, the immunostaining in benign 
pancreatic sections was successfully 
blocked by preincubating MAb 6G5 
with purified hCG. In placental and 
carcinoma sections the staining was 
also strongly reduced further con-
firming the specificity of the immu-
noreactivity. 
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Non-specific staining of the islets of 
Langerhans was observed with all 
antibodies in some benign pancreatic 
samples, which were otherwise im-
munohistochemically negative for 
hCGβ. The frequency of positive is-
lets increased with higher antibody 
concentrations, but the staining was 
unaffected by absorption of the anti-
body with hCG.  
 
In both benign and malignant cells 
the staining pattern of hCGβ was in-
tracytoplasmatic. Samples with posi-
tive immunohistochemical staining of 
hCGβ with both MAb 9C11 and the 
PAb, showed uniform and homoge-
neous staining, whereas samples 
positive only with MAb 9C11, had 
granular cytoplasmic staining in ap-
pearance. Negative controls lacked 
appropriate staining; the muscle ac-
tin antibody failed to stain exocrine 
or endocrine pancreatic cells in be-
nign pancreas tissue sections. 
 
Expression of hCGβ in serum 
and its diagnostic value in di-
gestive tract diseases (II) 
HCGβ in patients with benign and 
malignant digestive tract diseases  
Table 7 shows the frequency of ele-
vated serum concentrations of hCGβ, 
CEA, and CA 19-9 in patients with 
digestive tract diseases. The concen-
tration of hCGβ was elevated in 35% 
of the patients with gastrointestinal 
malignancies, and it was most fre-
quently elevated in patients with bile 
duct (56%), pancreatic (45%), and 
gastric cancer (41%). The median 
serum concentration of hCGβ was 1.3 
pmol/L (range <0.2 – 3018 pmol/L). 
In benign digestive tract diseases, 
the hCGβ level in serum was ele-
vated in 10% of the patients, and 
most frequently in patients with be-
nign pancreatic (16%), colorectal 
(13%), and gastric (13%) diseases. 
The median serum concentration was 
0.6 pmol/L (range <0.2 – 18.6 
pmol/L). 
 
Table 7. The number of patients with elevated serum hCGβ, CEA, and CA 19-9 in 142 patients with 
gastrointestinal malignancies and in 179 patients with benign digestive tract diseases (II). 
Malignancy n hCGβ 
>2 pmol/L
CEA 
>5 µg/L
CA 19-9 
>35 kU/L
Oesophageal 5 1 0 0 
Gastric  17 7 4 8 
Small bowel 3 0 1 1 
Colorectal 34 4 16 12 
Liver (hepatocellular) 20 7 2 8 
Liver (bile duct) 7 5 3 7 
Biliary (extrahepatic) 20 10 3 17 
Ampulla of Vater 3 1 0 2 
Pancreatic 33 15 10 26 
 142 50 39 81 
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Benign disease n hCGβ 
>2 pmol/L
CEA 
>5 µg/L
CA 19-9 
>35 kU/L
Oesophageal 4 0 0 0 
Gastric 8 1 1 1 
Small bowel 22 1 2 0 
Colorectal 15 2 0 0 
Liver 21 2 2 9 
Biliary 59 6 0 14 
Ampulla of Vater 1 0 0 0 
Pancreatic 38 6 2 8 
Abdominal pain 10 0 0 1 
 178 18 7 33 
 
 
In the benign disease group, ele-
vated serum levels of hCGβ had no 
association with any specific diagno-
sis. Elevated values were observed in 
acute and chronic pancreatitis, gall-
stones, acute and chronic cholecysti-
tis, primary biliary and liver cirrhosis, 
diverticulosis and diverticulitis, 
Crohn’s disease, and in one patient 
with several bleeding gastric ulcers 
and jaundice caused by gallstones. 
Some of the patients had additional 
chronic diseases, such as asthma, 
chronic obstructive bronchitis, rheu-
matoid arthritis, gout, glomeru-
lonephritis, IgA nephropathy, focal 
glomerulosclerosis, polycystic kid-
neys, renal insufficiency, and benign 
polyps. Of the 18 patients with be-
nign disease and elevated hCGβ 
level, six had died by December 
2000, all from various benign dis-
eases with no indication of malig-
nancy. 
 
The concentration of hCGβ in serum 
was significantly higher in patients 
with malignancies than with benign 
diseases (p< 0.001), but between 
males and females the difference in 
serum hCGβ level was insignificant 
(p= 0.507). Modest correlation was 
evident between serum hCGβ and 
CEA, hCGβ and CA 19-9, and CEA 
and CA 19-9 (rs= 0.288 - 0.460, p< 
0.001). The correlation was poor be-
tween the concentrations of hCGβ 
and aspartate aminotransferase 
(ASAT), alanine aminotransferase 
(ALAT), γ-glutamyl transferase 
(γ-GT), alkaline phosphatase (AFOS), 
bilirubin, amylase, creatinine, albu-
min, and C-reactive protein (CRP) 
(rs= -0.323 – 0.261 (p< 0.001)). 
 
Comparison of diagnostic value of 
hCGβ, CEA and CA 19-9 
The accuracy (the proportion of true 
positive and true negative results) 
was 66% for hCGβ, 66% for CEA, 
and 71% for CA 19-9 with the rec-
ommended cut-off values; the differ-
ence in accuracies was insignificant 
(p> 0.102). Furthermore, the accu-
racies of hCGβ, CEA, and CA 19-9 
were compared with ROC curve 
analysis yielding insignificant differ-
ences in AUC values (p= 0.458 – 
0.885).  
The markers hCGβ, CEA and CA 19-9 
all provided significant diagnostic 
information when included simulta-
neously in a logistic regression 
model, thus indicating that their 
combination improves accuracy (Ta-
ble 8). The best model was achieved 
incorporating the three markers as 
continuous variables with a logarith-
mic transformation of the marker 
values (Likelihood Ratio test p< 
0.01). With the logistic regression 
model, the probability of having can-
cer (the probability of cancer index, 
P) was calculated for each patient 
(P= ex/(ex + 1); x= –1.198 + 
0.474*ln(hCGβ) + 0.512*ln(CEA) + 
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0.226*ln(CA 19-9)). The index 
served as a diagnostic test, and its 
diagnostic validity was compared 
with hCGβ, CEA, and CA 19-9 with 
ROC curve analysis. The AUC value 
of the probability of cancer index was 
significantly higher than the AUC 
values for hCGβ, CEA, or CA 19-9 
(p= 0.009 – 0.049). 
 
 
Table 8. Logistic regression equation based on 142 patients with gastrointestinal malignancies and 
178 patients with benign digestive tract diseases (II). 
Variable Coefficient SE p-value Deviance 
increaseb
ORc 95% CI 
Ln hCGβa 0.474 0.141 <0.001 6.23 1.61 1.22-2.12 
Ln CEAa 0.512 0.142 <0.001 7.75 1.67 1.26-2.20 
Ln CA 19-9a 0.226 0.064 <0.001 6.77 1.25 1.11-1.42 
Constant -1.198 0.229  
a= natural logarithm of marker concentration, b= deviance increase of the model if the variable is excluded, c= OR 
represents a 1-unit increase on the logarithmic scale 
SE= standard error, OR= odds ratio, CI= confidence interval 
 
 
Prognostic value of hCGβ in 
colorectal, gastric and pan-
creatic cancer (III-V) 
Serum hCGβ in colorectal, gastric 
and pancreatic cancer (III-V) 
Table 9 shows the frequencies of ele-
vated serum tumour marker levels of 
hCGβ, CEA, CA 19-9, CA 242, and CA 
72-4 and their association with stage 
in patients with colorectal (III), gas-
tric (IV) and pancreatic (V) cancer. 
CEA was found to be the most sensi-
tive marker in colorectal cancer, and 
hCGβ in gastric and CA 19-9 in pan-
creatic cancer. The correlation be-
tween elevated marker concentra-
tions and advanced disease was sig-
nificant, except for CA 19-9 in gastric 
and pancreatic cancer (borderline 
significant), and for hCGβ and CEA in 
pancreatic cancer. 
 
Table 9. The frequency of tumour marker concentrations above the specified cut-off value, and the 
association of elevated marker values and stage with χ2-test in 204 patients with colorectal (III), 146 
patients with gastric (IV), and 160 patients with pancreatic cancer (V). 
 
hCGβ 
>2 pmol/L 
CEA 
>5 µg/L 
CA 19-9 
>37 kU/L 
CA 242 
>20 kU/L 
CA 72-4 
>6 kU/L 
Colorectal cancer 16% 44% 26% 36% 27% 
Correlation with stage p= 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001 
Gastric cancer 36% 18% 31% 34% 34% 
Correlation with stage p= 0.027 p= 0.014 p= 0.056 p= 0.015 p= 0.001 
Pancreatic cancer 63% 46% 87% 68% 39% 
Correlation with stage p= 0.174 p= 0.329 p= 0.074 p= 0.009 p= 0.002 
 
 
In colorectal cancer, median serum 
hCGβ level was 0.7 pmol/L (range 
<0.3 – 2600 pmol/L), and hCGβ was 
significantly higher in females than in 
males (p= 0.002). In gastric and 
pancreatic cancers, the median se-
rum concentrations of hCGβ were 1.2 
pmol/L (range <0.3– 237.4 pmol/L) 
and 2.8 pmol/L (range <0.5 – 1109 
pmol/L), respectively, with no corre-
lation between gender and hCGβ 
level (p> 0.243). The correlation be-
tween age and hCGβ level was 
strongest in colorectal cancer (rs= 
0.575, p< 0.001), but modest or 
poor in gastric and pancreatic cancer 
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(rs= 0.349, p< 0.001 and rs= 0.094, 
p= 0.235). The association between 
tumour location and elevated hCGβ 
was insignificant in colorectal and 
pancreatic cancers (p> 0.601), but 
significant in gastric cancer (p= 
0.047), the least frequently elevated 
marker values in patients with tu-
mours located in the corpus. Tumour 
size lacked correlation with elevated 
hCGβ in gastric and pancreatic can-
cer (p>0.184). In gastric cancer, 
hCGβ was significantly higher in pa-
tients with intestinal type tumours 
(p= 0.009). In pancreatic cancer, 
hCGβ had no correlation with clinical 
jaundice (p=0.550), nor with serum 
AFOS (rs= 0.002, p= 0.982) or 
bilirubin (rs= 0.047, p= 0.573). In all 
these cancer forms, the correlation 
between hCGβ and markers CEA, CA 
19-9, CA 242, and CA 72-4 was 
modest (rs= 0.102– 0.334, p< 
0.221). 
 
Univariate survival analysis of the 
prognostic value of hCGβ (III-V) 
In colorectal cancer (III), the overall 
disease specific 5-year survival was 
55%, and in Dukes’ A, B, C, and D 
tumours it was 89%, 77%, 52%, and 
3%, respectively. With Kaplan-Meier 
life-tables and log-rank-test, stage, 
resectability for cure, and tumour 
markers hCGβ, CEA, CA 19-9, CA 
242, and CA 72-4 were found to be 
prognostic factors (p< 0.001, table 
10).  
In gastric cancer (IV), the disease 
specific cumulative 2-year survival 
was 41%. In univariate analysis, 
prognostic factors were tumour 
stage, size, location and histology 
according to the Laurén classifica-
tion, resectability for cure, as well as 
markers hCGβ, CA 19-9, CA 242, and 
CA 72-4 (p< 0.035, table 10). CEA 
showed borderline significance (p= 
0.069). 
In pancreatic cancer (V), the overall 
disease specific 2-year survival was 
10%. Stage, tumour location and 
size, resectability for cure, and tu-
mour markers hCGβ, CEA and CA 72-
4 were prognostic factors in univari-
ate analysis (p< 0.026, table 10).  
 
Table 10. Kaplan-Meier life-table and log-rank test analyses of the correlations between preoperative 
characteristics and survival of 204 patients with colorectal cancer (III), of 146 patients with gastric can-
cer (IV), and of 160 patients with pancreatic cancer (V) (NA= not available). 
 Colorectal cancer Gastric cancer Pancreatic cancer 
Clinicopathological 
variable 
χ2 Statistic p-value χ2 Statistic p-value χ2 Statistic p-value 
Gender 0.20 0.654 0.16 0.693 1.40 0.237 
Stage 112.54 <0.001 79.90 <0.001 21.8 <0.001 
Tumour location 1.66 0.197 4.43 0.035 4.93 0.026 
Tumour size NA NA 55.78 <0.001 6.37 0.012 
Tumour histology 0.19 0.666 4.49 0.034 NA NA 
Resectability for cure 150.93 <0.001 70.57 <0.001 32.5 <0.001 
Clinical jaundice NA NA NA NA 1.99 0.159 
hCGβ >2 pmol/L 29.53 <0.001 16.34 <0.001 42.9 <0.001 
CEA >5 µg/L 42.98 <0.001 3.30 0.069 5.44 0.020 
CA 19-9 >37 kU/L 48.60 <0.001 7.76 0.005 1.31 0.252 
CA 242 >20 kU/L 37.33 <0.001 6.54 0.011 2.72 0.099 
CA 72-4 >6 kU/L 36.58 <0.001 19.97 <0.001 11.8 0.0006 
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Multivariate survival analysis of the 
prognostic value of hCGβ (III-V) 
In colorectal cancer (III), with Cox 
stepwise multivariate analysis, the 
strongest prognostic factor was 
found to be Dukes’ stage. Other in-
dependent prognostic factors were 
rectal tumour location and preopera-
tive serum markers hCGβ, CEA, and 
CA 72-4 (Table 11). When including 
only patients treated with curative 
resection (Dukes A, B, and C tu-
mours), the same independent prog-
nostic factors emerged, the strongest 
being CEA (Wald statistic 31.33, p< 
0.001, relative hazard (RH) 2.08), 
followed by rectal tumour location 
(Wald statistic 11.40, p= 0.001, RH 
3.21), hCGβ (Wald statistic 7.59, p= 
0.006, RH 1.53), stage (Wald statis-
tic 8.06, p= 0.018), and CA 72-4 
(Wald statistic 4.23, p= 0.040, RH 
1.24). 
 
Table 11. The independent prognostic factors in Cox stepwise regression analysis in 204 patients with 
colorectal cancer. CA 19-9, CA 242, age, gender, and histological type had insignificant prognostic 
value in the model (III). 
Covariate Wald statistic p-valueb RHc 95% CId
Dukes’ stage 58.12 < 0.001  
    Dukes A   
    Dukes B 1.70 NS 2.28 0.66-7.88 
    Dukes C 8.08 0.004 5.73 1.72-19.10 
    Dukes D 24.21 < 0.001 21.83 6.39-74.58 
Rectal tumour location 9.40 0.002 1.98 1.28-3.05 
Ln hCGβa 9.43 0.002 1.28 1.09-1.50 
Ln CEAa 7.80 0.005 1.20 1.06-1.36 
Ln CA 72-4a 8.68 0.003 1.21 1.07-1.38 
a Ln= natural logarithm of the marker concentration, b Significance level, c RH= Relative hazard, d CI= Confidence 
interval at 95% level 
 
 
In gastric cancer (IV), with multi-
variate analysis, the strongest prog-
nostic factor was found to be stage, 
followed by serum hCGβ, histological 
type according to Laurén classifica-
tion and CA 72-4 (table 12). Per-
forming the Cox multivariate regres-
sion analysis either in a backward or 
forward stepwise manner resulted in 
an identical outcome. Other clinical 
variables and tumour markers were 
found to convey insignificant prog-
nostic information by comparison. 
Exclusion of disseminated disease 
(stage IV) from the analysis yielded 
similar results; independent prognos-
tic factors were stage (Wald statistic 
21.10, p< 0.001), hCGβ (Wald statis-
tic 14.05, p< 0.001, RH 2.36), and 
histological type of the tumour (Wald 
statistic 11.31, p= 0.001, RH 4.31). 
Performing the analysis with ad-
vanced disease only (stages III and 
IV), hCGβ (Wald statistic 15.53, p< 
0.001, RH 1.51), tumour histology 
(Wald statistic 13.14, p< 0.001, RH 
2.48), stage (Wald statistic 12.66, 
p< 0.001, RH 2.37), and CA 72-4 
(Wald statistic 8.21, p= 0.004, RH 
1.20) emerged as independent prog-
nostic factors. Evaluating the tumour 
markers individually while adjusting 
the multivariate model for stage, 
hCGβ and CA 72-4 provided signifi-
cant prognostic information (p< 
0.007), contrary to CEA, CA 19-9 
and CA 242 (p> 0.212). 
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Table 12. Independent prognostic factors in Cox stepwise regression analysis in 146 patients with 
gastric cancer. CEA, CA 19-9, CA 242, age, gender, tumour location and size, and resectability for 
cure provided insignificant prognostic information (IV). 
Covariate Wald statistic p-valueb RHc 95% CId
Stage 47.37 < 0.001  
   Stage I   
   Stage II 3.41 0.065 3.72 0.92- 14.96 
   Stage III 19.41 < 0.001 11.05 3.79- 32.15 
   Stage IV 36.35 < 0.001 28.13 9.51- 83.23 
Tumour histology 13.82 < 0.001 2.47 1.53- 3.98 
Ln hCGβa 16.87 < 0.001 1.52 1.25- 1.86 
Ln CA 72-4a 6.68 0.010 1.17 1.04- 1.33 
a Ln= natural logarithm of the marker concentration, b Significance level, c RH= Relative hazard, d CI= Confidence 
interval at 95% level 
 
 
In pancreatic cancer (V), hCGβ, CA 
72-4 and stage emerged as the fac-
tors providing independent prognos-
tic information (table 13). Other 
clinical characteristics and tumour 
markers contributed only insignifi-
cant prognostic information. The Cox 
multivariate regression analysis was 
performed both in a backward and 
forward stepwise manner with con-
sistent results. Adjustment of the 
model for resectability for cure pro-
vided the following independent 
prognostic factors: curative resection 
(Wald statistic 17.47, p< 0.0001, RH 
0.35), hCGβ (Wald statistic 41.60, 
p< 0.0001, RH 1.45), and CA 72-4 
(Wald statistic 15.77, p< 0.0001, RH 
1.28). In addition, excluding stage IV 
from the analysis, hCGβ (Wald statis-
tic 18.29, p< 0.001, RH 1.83) and 
curative resection (Wald statistic 
10.82, p= 0.001, RH 0.34) emerged 
as independent prognostic factors. 
Evaluating the markers hCGβ, CEA, 
CA 19-9, CA 242, and CA 72-4 indi-
vidually but adjusting for stage, all 
markers were found to convey sig-
nificant prognostic information in the 
multivariate model (p< 0.011). Fur-
ther adjustment of the model for the 
presence of jaundice did not alter the 
results. 
 
Table 13. Independent prognostic factors in Cox stepwise regression analysis in 160 patients with 
pancreatic cancer. CEA, CA 19-9, CA 242, gender, age, tumour location and size, and presence of 
jaundice provided insignificant prognostic information (V). 
Covariate Wald statistic p-valueb RHc 95% CId 
Stage 8.74 0.033  
   Stage I   
   Stage II 3.20 0.074 2.03 0.93-4.42 
   Stage III 2.63 0.105 1.91 0.87-4.17 
   Stage IV 7.60 0.006 2.73 1.34-5.58 
Ln hCGβa 47.96 < 0.001 1.46 1.31-1.63 
Ln CA 72-4a 14.83 < 0.001 1.26 1.12-1.42 
a Ln= natural logarithm of the marker concentration, b Significance level, c RH= Relative hazard, d CI= Confidence 
interval at 95% level 
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DISCUSSION 
Tissue and serum expression of 
hCGβ in digestive tract dis-
eases 
The present study confirmed previ-
ous findings that various gastrointes-
tinal malignancies express hCG or its 
free β subunit (Braunstein et al., 
1973; McManus et al., 1976; Hattori 
et al., 1978; Blackman et al., 1980; 
Marcillac et al., 1992). Current re-
sults demonstrated positive hCGβ 
tissue immunostaining that was most 
frequent in gastric and pancreatic 
carcinomas and extrahepatic cholan-
giocarcinoma. Accordingly in serum, 
the hCGβ level was elevated most 
frequently in patients with bile duct, 
pancreatic, and gastric cancer.  
The sensitivities observed in the pre-
sent study were also in concordance 
with previous findings on the expres-
sion of hCGβ. In gastric cancer, the 
hCGβ tissue expression has been re-
ported up to about half of the cases 
both in tissues and serum (Manabe 
et al., 1985; Wittekind et al., 1986; 
Fukayama et al., 1987b; Birkenfeld 
et al., 1989; Yakeishi et al., 1990; 
Marcillac et al., 1992; Webb et al., 
1996). Although elevated serum con-
centrations of hCGβ have been 
shown to be common in pancreatic 
cancer (Alfthan et al., 1992b; Marcil-
lac et al., 1992; Syrigos et al., 
1998), the incidence of immunohis-
tochemical expression of hCGβ has 
not been reported in this disease. In 
biliary cancer, the incidence of hCG-
immunoreactivity has been found in 
up to about one fourth of the cases 
(Nakanuma et al., 1986; Nonomura 
et al., 1989), and the frequency of 
elevated serum levels has been 
shown to be as high as 86% (Alfthan 
et al., 1992b). In colorectal cancer, 
the tissue expression of hCGβ has 
been reported in up to about half of 
the cases (Shousha et al., 1986; 
Campo et al., 1987; Fukayama et al., 
1987a; Yamaguchi et al., 1989; 
Connelly et al., 1993; Webb et al., 
1995; Kido et al., 1996), and the 
serum expression in up to about one 
third of the cases (Mercer & Talamo, 
1985; Birkenfeld et al., 1989; Webb 
et al., 1995; Carpelan-Holmström et 
al., 1996a). 
 
Positive immunostaining has previ-
ously been reported in normal and 
inflammatory gastric tissues (Manabe 
et al., 1985; Yakeishi et al., 1990), 
and in normal pancreatic ductal 
epithelium with the Dako anti-hCG 
PAb (Graeme-Cook et al., 1990). In 
addition, moderately elevated serum 
levels of hCG or hCGβ have been 
shown in patients with gastric and 
duodenal ulcers, enteritis, ulcerative 
colitis, liver cirrhosis, pancreatitis, 
and benign biliary obstruction 
(Vaitukaitis et al., 1976; Alfthan et 
al., 1992b; Hoermann et al., 1992; 
Syrigos et al., 1998).  
The current results on benign diges-
tive tract diseases were consistent 
with the previous findings. Tissue 
expression of hCGβ was observed in 
benign pancreatic acinar cells and 
biliary tract epithelium. The findings 
were also confirmed with three addi-
tional monoclonal antibodies, and the 
specificity of the immunoreactivity 
was verified in benign tissues by 
blocking the staining through absorp-
tion of the antibody with hCG. In ad-
dition, moderately elevated serum 
levels of hCGβ were evident in pa-
tients with gastric ulcers, Crohn’s 
disease, diverticulosis, liver cirrhosis, 
cholecystitis and gallstones, and 
pancreatitis. The patient presenting 
with elevated serum hCGβ in the be-
nign gastric disease group was 
hospitalized due to several bleeding 
ulcers; however, she had biliary ob-
struction as well, which may have in 
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part accounted for the elevated level 
of hCGβ.  
 
In the present study, the same 
monoclonal antibody was applied 
both in immunohistochemistry and 
serum assays (MAb 9C11). The MAb 
identifies specifically the free β sub-
unit of hCG, and it has been shown 
to be sensitive for the free hCGβ in 
serum assays (Alfthan et al., 1988; 
Alfthan et al., 1992b). Previously 
Bellet et al. (1997) suggested that 
some hCGβ immunoassays fail to be 
sensitive enough to detect the hCGβ 
secretion of normal cells, which have 
a low transcriptional activity of hCGβ 
genes.  
The present study confirmed that the 
MAb is also suited for immunohisto-
chemistry and apparently is able to 
detect the low hCGβ expression in 
benign tissues. Current results also 
provided further support for the sug-
gestion that free hCGβ is secreted 
not only by the pituitary gland (Ho-
ermann et al., 1990), but also by 
normal and benign non-trophoblastic 
cells of varying histological origin 
(Bellet et al., 1997), which in turn 
may reflect the low levels of hCGβ 
observed in sera of healthy non-
pregnant individuals. 
 
The tissue staining of MAb 9C11 was 
compared in the present study with a 
commercial PAb. The differences ob-
served in both benign and malignant 
tissues between the two antibodies 
may be explained by the different 
sensitivity and specificity of the anti-
bodies. Most of the previous studies 
on immunohistochemical expression 
of hCGβ in gastrointestinal cancers 
have been performed with the PAb 
from Dakopatts. However, this PAb 
has also been reported to cross-react 
with intact hCG, hCGα, LH, TSH, 
FSH, LHβ, TSHβ, and FSHβ (Morrish 
et al., 1987), which may explain the 
more frequent and diffuse staining 
observed in some cancers. In addi-
tion, neuroendocrine tumours, such 
as carcinoids and islet cell carcino-
mas, have been shown to express 
the α subunit of hCG (Blackman et 
al., 1980), which may account for 
the findings in small intestinal carci-
noids in the present study. The ex-
pression of other glycoprotein hor-
mones and their subunits has not 
been reported in gastrointestinal tis-
sues; consequently it remains to be 
determined whether the crossreactiv-
ity of the PAb with other hormones 
can explain the findings. 
 
Diagnostic value of hCGβ and 
logistic regression algorithm in 
digestive tract diseases 
Traditionally the value of a diagnostic 
test has been assessed by sensitiv-
ity, specificity and accuracy of the 
variable at certain predetermined 
cut-off levels. Moreover, ROC curves 
have been constructed and accura-
cies of two diagnostic tests have 
been compared by calculating and 
comparing the AUC values of the 
ROC curves (Hanley & McNeil, 1982; 
Hanley & McNeil, 1983). However, 
with these models it is difficult to 
combine and compare the value of 
two or more diagnostic variables and 
tests, such as tumour markers.  
Consequently, multivariate statistical 
methods have been developed to 
address this problem. Logistic re-
gression is a multivariate model as-
sessing the probability of binary out-
comes, such as the patient having 
malignant or benign disease (Hosmer 
& Lemeshow, 2000). The LR model 
quantifies the contribution of individ-
ual variables without predetermined 
cut-off values and is suitable for 
comparing the validity of several di-
agnostic variables or tests, not only 
tumour markers, but also other fac-
tors such as clinicopathological pa-
tient characteristics. The LR model 
combines the variables optimally in 
constructing diagnostic algorithms, 
which can be used to estimate the 
probability of a disease yielding a 
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diagnostic risk index on a scale from 
0 to 1. This risk index can be in turn 
applied as a diagnostic test 
determining its accuracy for example 
with ROC-curve analysis. Previously, 
risk calculation based on logistic 
regression or neural networks has 
been shown to be useful in the 
diagnosis of prostate cancer (Finne 
et al., 2000). 
In the present study, only insignifi-
cant differences in diagnostic accu-
racy were observed between the in-
dividual markers hCGβ, CEA and CA 
19-9. Yet each marker provided sig-
nificant diagnostic information in lo-
gistic regression analysis. With an 
algorithm based on the LR model, 
the combination of hCGβ, CA 19-9 
and CEA moderately improved the 
accuracy in this heterogeneous group 
of gastrointestinal malignancies. 
However, these results are prelimi-
nary and the possible diagnostic 
value of hCGβ and tumour marker 
combinations in each disease group 
must be ascertained in a larger 
group of patients. It is also notewor-
thy that although the LR model may 
be a promising mathematical method 
and diagnostic tool to improve accu-
racy, and in future it may help the 
clinician in deciding the patient ex-
amination protocol, the definitive 
diagnosis of digestive tract cancers 
will always rely on cyto- or histologi-
cal findings from fine needle biopsies 
or biopsies obtained by endoscopic 
procedures. 
 
Prognostic value of hCGβ in 
colorectal, gastric and pan-
creatic cancer 
The anatomic extent of the spread of 
the disease reflected by tumour 
stage is generally considered to be 
the strongest prognostic factor in 
digestive tract malignancies such as 
colorectal, gastric and pancreatic 
cancers (Gospodarowicz et al., 
2001). To find additional tools and 
potential prognostic factors to help 
select patients for possible adjuvant 
therapies, the role and prognostic 
value of tumour markers has also 
been evaluated, with CEA and CA 19-
9 as the most studied markers in 
gastrointestinal cancers. 
 
CEA has been shown to have inde-
pendent prognostic value in colorec-
tal cancer (Webb et al., 1995; Carri-
quiry & Piñeyro, 1999) and in gastric 
cancer (Maehara et al., 1994; Na-
kane et al., 1994; Reiter et al., 
1997a; Tachibana et al., 1998; Toc-
chi et al., 1998; Ishigami et al., 
2001). In pancreatic cancer, CEA has 
been suggested to provide significant 
prognostic information (Kalser et al., 
1978; Taylor et al., 1992; Yasue et 
al., 1994; Takeuchi et al., 1998). CA 
19-9 has been shown to be an inde-
pendent prognostic factor in colorec-
tal cancer (Filella et al., 1992), in 
gastric cancer (Kodera et al., 1996; 
Reiter et al., 1997a; Tocchi et al., 
1998) and in pancreatic cancer (Gat-
tani et al., 1996).  
Of the other tumour markers evalu-
ated in the present study, CA 242 
has been previously shown to have 
independent prognostic value in colo-
rectal cancer (Carpelan-Holmström 
et al., 1996a), and in pancreatic can-
cer, elevated levels of CA 242 have 
been suggested to indicate poor 
prognosis (Lundin et al., 1995). CA 
72-4 has been suggested to correlate 
with adverse outcome in colorectal 
cancer (Lindmark et al., 1996), and 
in gastric cancer, CA 72-4 has been 
reported to be an independent prog-
nostic factor (Gaspar et al., 2001). 
Serum hCGβ has been previously 
shown to provide independent prog-
nostic information in colorectal can-
cer (Webb et al., 1995; Carpelan-
Holmström et al., 1996a; Lundin et 
al., 2001), in advanced gastric can-
cer (Webb et al., 1996), and in pan-
creatic cancer (Syrigos et al., 1998). 
However, to the best of the author's 
knowledge, no studies exist compar-
ing the prognostic value of the five 
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tumour markers, CEA, CA 19-9, CA 
242, CA 72-4, and hCGβ, in gastroin-
testinal cancers. 
 
The current results suggest that 
hCGβ has prognostic value in diges-
tive tract malignancies. Serum hCGβ 
was found to be a prognostic factor 
in univariate survival analysis in co-
lorectal, gastric and pancreatic can-
cer. Furthermore, in these cancers 
hCGβ was found to be the strongest 
prognostic tumour marker in multi-
variate analysis compared with 
markers CEA, CA 19-9, CA 242, and 
CA 72-4. It is also noteworthy that 
hCGβ provided independent prognos-
tic information in colorectal, gastric 
and pancreatic cancer even if dis-
seminated disease (Dukes D' or 
stage IV tumours) was excluded 
from the analysis.  
 
In colorectal cancer, the variables 
providing independent prognostic 
information in the multivariate analy-
sis were (in order of importance) 
Dukes’ stage, serum hCGβ, rectal 
tumour location, and serum CA 72-4 
and CEA. The results were similar 
also in gastric cancer: the strongest 
prognostic factor was stage, followed 
by hCGβ, tumour histology and CA 
72-4. When including only patients 
with stage III and IV gastric tumours 
in the analysis, hCGβ, CA 72-4 and 
resectability for cure emerged as in-
dependent prognostic factors concur-
ring with the previous report on 
prognostic value of hCGβ in ad-
vanced gastric cancer (Webb et al., 
1996). 
 
In pancreatic cancer, the strongest 
independent prognostic factor in the 
multivariate survival analysis was 
preoperative hCGβ followed by CA 
72-4 and stage. The observation that 
markers were stronger prognostic 
factors than stage most probably re-
flects the stage distribution of the 
patient material of the present study. 
The majority of patients had stage IV 
disease, with a rather small number 
of stage I to III tumours. Unfortu-
nately this is a reflection of clinical 
practice whereby most pancreatic 
cancer patients present with ad-
vanced disease already at the time of 
diagnosis. However, it is likely that 
stage would emerge as the strongest 
prognostic factor in a study compris-
ing more patients with local disease. 
Most likely as another reflection of 
the stage distribution of the present 
study, the possibility of curative re-
section was observed to be a 
stronger prognostic factor than stage 
in pancreatic cancer. However, inclu-
sion of resectability for cure in the 
model did not alter the results on 
prognostic value of the markers, 
hCGβ and CA 72-4 still remained as 
independent prognostic factors to-
gether with curative resection. 
 
Value of hCGβ measurement 
in digestive tract diseases  
Previously hCGβ was considered to 
be a marker for trophoblastic disease 
only. Therefore, commercial assays 
for quantification of free β subunit of 
hCG are mainly designed for screen-
ing and management of pregnancy 
related disorders when the concen-
tration of hCGβ is usually relatively 
high. However, hCGβ can also serve 
as a marker for non-trophoblastic 
disorders when the majority of pa-
tients have very low concentrations 
of hCGβ in serum. Therefore, the ac-
curacy and clinical value of hCGβ 
measurement is highly dependent on 
the detection limit and the specificity 
of the assay in use. The hCGβ immu-
noassay (IFMA) applied in the pre-
sent study is based on a monoclonal 
antibody and is highly sensitive and 
specific for the free hCGβ subunit 
(Alfthan et al., 1988; Alfthan et al., 
1992a; Alfthan et al., 1992b). It has 
no significant crossreactivity with 
hCG, which may occur at concentra-
tions up to 20 pmol/L in non-
pregnant patients with benign condi-
Discussion 
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tions (Alfthan et al., 1992a). Since 
the hCG immunoreactivity expressed 
by non-trophoblastic tumours is al-
most exclusively hCGβ, it is likely 
that this IFMA can provide optimal 
diagnostic accuracy. 
 
Current results indicate that hCGβ is 
expressed in various gastrointestinal 
diseases, both in tissues and in se-
rum. HCGβ was also observed to be 
the strongest prognostic tumour 
marker compared with CEA, CA 19-9, 
CA 242, and CA 72-4, in the three 
most common digestive tract malig-
nancies of developed countries, 
namely colorectal, gastric and pan-
creatic cancers. It remains to be in-
vestigated whether elevated serum 
hCGβ levels in digestive tract malig-
nancies signify increased production 
of hCGβ by tumour cells or alterna-
tively enhanced shedding or release 
into circulation. Increased hCGβ pro-
duction might denote aggressive be-
haviour of tumour cells associating 
with mechanisms of tumour invasion. 
However, enhanced shedding might 
indicate that the tumour has spread 
through the natural barriers of dis-
tinct histological structures.  
 
Although it has been suggested that 
hCGβ has auto- or paracrine effect 
on tumour cell growth (Gillott et al., 
1996), the true biological function of 
hCGβ and the mechanisms of its ac-
tion continue to be intriguing ques-
tions and warrant further analysis. 
More studies are also required to 
corroborate the current findings and 
to validate the prognostic value of 
hCGβ particularly in local disease 
with a possibility of curative treat-
ment. Furthermore, it remains to be 
shown whether hCGβ has also pre-
dictive value and could be applied in 
the choice and monitoring of treat-
ment in patients with digestive tract 
cancers. 
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CONCLUSIONS 
1. Monoclonal antibodies specific for the free β subunit of hCG are sensitive 
and specific for detection of hCGβ in tissues. In the present study, the tissue ex-
pression of hCGβ was evident most frequently in gastric and pancreatic carcino-
mas and extrahepatic cholangiocarcinoma. However, positive immunostaining 
was also observed in benign pancreatic acinar cells and biliary tract epithelium. 
The results confirm previous findings on hCGβ expression in gastrointestinal dis-
eases and also provide further support for hCGβ as a potential tumour marker for 
digestive tract malignancies (I). 
 
 
2. The serum hCGβ level was elevated most frequently in bile duct, pancreatic 
and gastric cancer, thus confirming the findings with immunohistochemistry. The 
diagnostic value of hCGβ serum test was additive to that of CEA and CA 19-9 in 
digestive tract cancers. The probability of cancer index based on logistic regres-
sion analysis provided better accuracy as a diagnostic test than the markers 
alone. Although the LR algorithm may be a promising method to obtain addi-
tional diagnostic information, the definitive diagnosis of digestive tract cancers 
continues to rely on cyto- or histological findings from biopsies (II). 
 
 
3. In colorectal cancer, Dukes’ stage was the strongest independent prognostic 
factor with preoperative serum hCGβ as the strongest prognostic tumour marker 
followed by CA 72-4, and CEA (III). 
 
 
4. In gastric cancer, stage and serum hCGβ had independent prognostic value 
in addition to tumour histology and serum CA 72-4. HCGβ was observed to be 
the strongest prognostic tumour marker (IV). 
 
 
5. In pancreatic cancer, hCGβ, CA 72-4 and stage provided independent prog-
nostic information. Serum hCGβ was found as the strongest prognostic tumour 
marker (V). 
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SUMMARY 
Tumour markers may be useful in 
the primary diagnosis of cancer, in 
the follow-up of disease and monitor-
ing the response to treatment, as 
well as in the prognostic evaluation 
of cancer patients. HCG is a glyco-
protein hormone normally secreted 
not only by placenta, but also by 
neoplastic trophoblastic cells. HCG 
has been in clinical use in pregnancy 
and pregnancy related disorders, as 
well as in choriocarcinoma and tes-
ticular germ cell tumours. HCG is 
composed of two distinct subunits, α 
and β. The free β subunit of hCG has 
been shown to be expressed in vari-
ous non-trophoblastic malignancies, 
such as bladder and lung cancers, 
and also in digestive tract malignan-
cies. In the present study, the tissue 
and serum expression of hCGβ was 
investigated in various gastrointesti-
nal cancers, wherein the same MAb 
specific for the free hCGβ was ap-
plied both in immunohistochemical 
method and in serum assays. The 
prognostic value of serum hCGβ was 
assessed in colorectal, gastric and 
pancreatic cancers, the three most 
common digestive tract cancer forms 
in developed countries. 
 
In the present study, tissue expres-
sion of hCGβ was observed in various 
gastrointestinal cancers, as well as in 
benign pancreatic and biliary tissues. 
The positive immunostaining was 
most frequent in gastric and pancre-
atic carcinomas and in extrahepatic 
cholangiocarcinoma; the incidence of 
tissue expression of hCGβ had not 
been reported previously in pancre-
atic adenocarcinoma. Monoclonal an-
tibodies specific for the free hCGβ, 
previously applied in serum assays, 
were also demonstrated to be sensi-
tive and specific for detection of 
hCGβ in tissues. The results con-
firmed previous findings on hCGβ 
expression and provided further sup-
port for the role of hCGβ as a tumour 
marker in digestive tract malignan-
cies. 
 
The expression of hCGβ was ob-
served also in serum of patients with 
digestive tract malignancies with the 
hCGβ serum test having additive di-
agnostic value to that of CEA and CA 
19-9. As a diagnostic test, the prob-
ability of cancer index based on a 
logistic regression model and com-
bining the three markers, improved 
the accuracy compared with the 
markers alone. In the present study, 
the hCGβ concentration in serum was 
elevated most frequently in bile duct, 
pancreatic, and gastric cancers. 
However, further studies are war-
ranted to establish the diagnostic 
value of serum hCGβ compared to 
other markers in the individual can-
cer forms. Furthermore, at present 
the clinical relevance of the current 
findings is moderate, because al-
though the LR model may be a 
promising diagnostic tool to improve 
accuracy, the definitive diagnosis of 
digestive tract cancers must be 
based on cyto- or histological find-
ings from biopsies. 
 
HCGβ was observed to be an inde-
pendent prognostic factor in colorec-
tal, gastric and pancreatic cancers, 
furthermore, it was found to be the 
strongest prognostic factor compared 
with CEA, CA 19-9, CA 242, and CA 
72-4. Other factors providing inde-
pendent prognostic information in 
colorectal cancer were Dukes’ stage, 
rectal tumour location, and tumour 
markers CEA and CA 72-4. In gastric 
cancer, in addition to hCGβ, stage, 
histology of the tumour according to 
the Laurén classification, and CA 72-
4 had independent prognostic value. 
In pancreatic cancer, in addition to 
hCGβ, the strongest independent 
prognostic factors were observed to 
Johanna Louhimo 
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be CA 72-4 and stage of the tumour. 
In colorectal, gastric and pancreatic 
cancer, hCGβ remained as an inde-
pendent prognostic factor also when 
disseminated disease (Dukes' stage 
D or stage IV) was excluded from the 
analysis.  
Further studies are required to es-
tablish the prognostic value of hCGβ 
in local disease with a possibility of 
curative treatment, as well as its 
predictive value and possible useful-
ness in selection of patients for adju-
vant therapies in digestive tract ma-
lignancies. 
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